Bristol Myers (NYSE: BMY) Q1 2026 revenue edges up 3%
Filing Impact
Filing Sentiment
Form Type
10-Q
Bristol-Myers Squibb reported first-quarter 2026 total revenues of $11,489 million, up 3% from 2025, as strong demand in its Growth Portfolio and for Eliquis offset generic erosion in legacy cancer drugs and pricing pressure, especially in the U.S.
GAAP diluted EPS rose to $1.31 from $1.20, helped by lower amortization of acquired intangibles, while non-GAAP EPS fell to $1.58 from $1.80 mainly because diabetes royalty income ended in 2025. Operating cash flow was $1,104 million, and the company continues a restructuring plan targeting about $2.5 billion in charges and $2.0 billion in annual cost savings by 2027.
Positive
- None.
Negative
- None.
Key Figures
Total Revenues: $11,489 million
Net earnings attributable to BMS: $2,677 million
GAAP diluted EPS: $1.31
+5 more
8 metrics
Total Revenues
$11,489 million
Three months ended March 31, 2026; up 3% year over year
Net earnings attributable to BMS
$2,677 million
Three months ended March 31, 2026
GAAP diluted EPS
$1.31
Three months ended March 31, 2026 vs. $1.20 in 2025
Non-GAAP diluted EPS
$1.58
Three months ended March 31, 2026 vs. $1.80 in 2025
Net cash from operating activities
$1,104 million
Three months ended March 31, 2026
Total Assets
$86,476 million
Balance sheet as of March 31, 2026
Long-term debt
$42,152 million
As of March 31, 2026, excluding current portion
Restructuring Plan expected charges
$2.5 billion
Total expected charges under 2023 Restructuring Plan through 2027
Key Terms
GTN adjustments, Acquired IPRD, cash flow hedges, contingent value rights, +1 more
5 terms
GTN adjustments financial
"The following table summarizes the GTN adjustments"
Acquired IPRD financial
"Acquired IPRD charges resulting from upfront or contingent milestone payments"
cash flow hedges financial
"Derivatives qualifying as cash flow hedges"
A cash flow hedge is an accounting label companies use when they enter financial contracts—like currency or interest-rate agreements—to protect expected future cash payments or receipts from unpredictable moves. For investors, it signals that the company is trying to smooth out future cash variability (think of locking in a price to avoid surprises), which can reduce reported profit swings but also means the company has exposure to derivative instruments and their associated risks.
contingent value rights financial
"Includes the fair value of contingent value rights associated with the Mirati acquisition"
Contingent value rights are special financial instruments that give their holder the potential to receive additional payments if certain future events or conditions happen, such as the achievement of specific business milestones. They are like a promise of extra rewards that depend on how well a project or company performs later on. Investors care about them because they offer a chance for extra gains but also carry uncertainty, as the extra payments are not guaranteed.
net investment hedges financial
"Derivatives designated as net investment hedges"
A net investment hedge is a financial step a company takes to protect the reported value of its ownership in foreign subsidiaries from swings in exchange rates. By using derivatives or foreign‑currency borrowings to offset translation gains or losses, the company reduces how much its balance sheet and reported equity jump around when currencies move — like locking a price tag on a foreign store so its value in the home currency stays steadier for investors.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 10-Q
___________________________
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2026
OR
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to _______
Commission File Number 001-01136
___________________________
(Exact name of registrant as specified in its charter)
___________________________
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||
(Address of principal executive offices) (Zip Code)
(609 ) 252-4621
(Registrant’s telephone number, including area code)
___________________________
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Accelerated filer ☐ | Non-accelerated filer ☐ | Smaller reporting company | Emerging growth company | |||||||||||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
At April 21, 2026, there were 2,042,071,247 shares outstanding of the Registrant’s $0.10 par value common stock.
BRISTOL-MYERS SQUIBB COMPANY
INDEX TO FORM 10-Q
March 31, 2026
| PART I—FINANCIAL INFORMATION | |||||
| Item 1. | |||||
Financial Statements: | |||||
Consolidated Statements of Earnings and Comprehensive Income/(Loss) | 3 | ||||
Consolidated Balance Sheets | 4 | ||||
Consolidated Statements of Cash Flows | 5 | ||||
Notes to Consolidated Financial Statements | 6 | ||||
| Item 2. | |||||
Management’s Discussion and Analysis of Financial Condition and Results of Operations | 25 | ||||
| Item 3. | |||||
Quantitative and Qualitative Disclosure About Market Risk | 40 | ||||
| Item 4. | |||||
Controls and Procedures | 40 | ||||
| PART II—OTHER INFORMATION | |||||
| Item 1. | |||||
Legal Proceedings | 40 | ||||
| Item 1A. | |||||
Risk Factors | 40 | ||||
| Item 2. | |||||
Unregistered Sales of Equity Securities and Use of Proceeds | 41 | ||||
| Item 5. | |||||
Other Information | 41 | ||||
| Item 6. | |||||
Exhibits | 42 | ||||
Summary of Abbreviated Terms | 43 | ||||
Signatures | 44 | ||||
* Indicates brand names of products which are trademarks not owned by BMS. Specific trademark ownership information is included in the Exhibit Index at the end of this Quarterly Report on Form 10-Q.
PART I—FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF EARNINGS
Dollars in millions, except per share data
(UNAUDITED)
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Net product sales | $ | $ | |||||||||||||||||||||
| Alliance and other revenues | |||||||||||||||||||||||
| Total Revenues | |||||||||||||||||||||||
Cost of products sold(a) | |||||||||||||||||||||||
Selling, general and administrative | |||||||||||||||||||||||
| Research and development | |||||||||||||||||||||||
| Acquired IPRD | |||||||||||||||||||||||
| Amortization of acquired intangible assets | |||||||||||||||||||||||
Other (income)/expense, net | |||||||||||||||||||||||
| Total Expenses | |||||||||||||||||||||||
| Earnings/(Loss) before income taxes | |||||||||||||||||||||||
Income tax provision | |||||||||||||||||||||||
| Net earnings/(loss) | |||||||||||||||||||||||
| Noncontrolling interest | |||||||||||||||||||||||
| Net earnings/(loss) attributable to BMS | $ | $ | |||||||||||||||||||||
| Earnings/(Loss) per common share: | |||||||||||||||||||||||
| Basic | $ | $ | |||||||||||||||||||||
| Diluted | |||||||||||||||||||||||
(a) Excludes amortization of acquired intangible assets .
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)
Dollars in millions
(UNAUDITED)
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
Net earnings/(loss) | $ | $ | |||||||||||||||||||||
| Other comprehensive income/(loss), net of taxes and reclassifications to earnings: | |||||||||||||||||||||||
| Derivatives qualifying as cash flow hedges | ( | ||||||||||||||||||||||
| Pension and postretirement benefits | |||||||||||||||||||||||
| Marketable debt securities | ( | ||||||||||||||||||||||
| Foreign currency translation | |||||||||||||||||||||||
| Total other comprehensive income/(loss) | ( | ||||||||||||||||||||||
Comprehensive income/(loss) | |||||||||||||||||||||||
Comprehensive income/(loss) attributable to noncontrolling interest | |||||||||||||||||||||||
Comprehensive income/(loss) attributable to BMS | $ | $ | |||||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
3
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED BALANCE SHEETS
Dollars in millions
(UNAUDITED)
| ASSETS | March 31, 2026 | December 31, 2025 | |||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
| Marketable debt securities | |||||||||||
| Receivables | |||||||||||
| Inventories | |||||||||||
| Other current assets | |||||||||||
| Total Current assets | |||||||||||
| Property, plant and equipment | |||||||||||
| Goodwill | |||||||||||
| Other intangible assets | |||||||||||
| Deferred income taxes | |||||||||||
Marketable debt securities | |||||||||||
| Other non-current assets | |||||||||||
| Total Assets | $ | $ | |||||||||
| LIABILITIES | |||||||||||
| Current liabilities: | |||||||||||
| Short-term debt obligations | $ | $ | |||||||||
| Accounts payable | |||||||||||
| Other current liabilities | |||||||||||
| Total Current liabilities | |||||||||||
| Deferred income taxes | |||||||||||
| Long-term debt | |||||||||||
| Other non-current liabilities | |||||||||||
| Total Liabilities | |||||||||||
Commitments and Contingencies (see Note 18) | |||||||||||
| EQUITY | |||||||||||
| BMS Shareholders’ equity: | |||||||||||
| Preferred stock | |||||||||||
| Common stock | |||||||||||
| Capital in excess of par value of stock | |||||||||||
| Accumulated other comprehensive loss | ( | ( | |||||||||
| Retained earnings | |||||||||||
| Less cost of treasury stock | ( | ( | |||||||||
| Total BMS Shareholders’ equity | |||||||||||
| Noncontrolling interest | |||||||||||
| Total Equity | |||||||||||
| Total Liabilities and Equity | $ | $ | |||||||||
The accompanying notes are an integral part of these consolidated financial statements.
4
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF CASH FLOWS
Dollars in millions
(UNAUDITED)
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Cash Flows From Operating Activities: | |||||||||||
| Net earnings/(loss) | $ | $ | |||||||||
| Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization, net | |||||||||||
| Deferred income taxes | |||||||||||
| Stock-based compensation | |||||||||||
| Impairment charges | |||||||||||
| Divestiture gains and royalties | ( | ( | |||||||||
| Acquired IPRD | |||||||||||
Equity investment (gains)/losses, net | ( | ||||||||||
| Other adjustments | |||||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Receivables | |||||||||||
| Inventories | ( | ||||||||||
| Accounts payable | ( | ||||||||||
| Rebates and discounts | ( | ( | |||||||||
| Income taxes payable | |||||||||||
| Other | ( | ( | |||||||||
Net cash provided by operating activities | |||||||||||
| Cash Flows From Investing Activities: | |||||||||||
| Sale and maturities of marketable debt securities | |||||||||||
| Purchase of marketable debt securities | ( | ( | |||||||||
| Proceeds from sales of equity investments | |||||||||||
| Capital expenditures | ( | ( | |||||||||
| Divestiture and other proceeds | |||||||||||
| Acquisition and other payments, net of cash acquired | ( | ( | |||||||||
Net cash provided by/(used in) investing activities | ( | ( | |||||||||
| Cash Flows From Financing Activities: | |||||||||||
Other short-term financing obligations, net | |||||||||||
Repayments of long-term debt | ( | ||||||||||
| Dividends | ( | ( | |||||||||
| Stock option proceeds and other, net | ( | ( | |||||||||
Net cash provided by/(used in) financing activities | ( | ( | |||||||||
| Effect of exchange rates on cash, cash equivalents and restricted cash | ( | ||||||||||
Increase/(decrease) in cash, cash equivalents and restricted cash | ( | ||||||||||
| Cash, cash equivalents and restricted cash at beginning of period | |||||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | $ | |||||||||
The accompanying notes are an integral part of these consolidated financial statements.
5
Note 1. BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS
Basis of Consolidation
Bristol-Myers Squibb Company ("BMS", "we", "our", "us" or "the Company") prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position of the Company as of March 31, 2026 and December 31, 2025 and the results of operations and cash flows for the three months ended March 31, 2026 and 2025. All intercompany balances and transactions have been eliminated. These consolidated financial statements and the related footnotes should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2025 included in the 2025 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document.
Certain amounts in this Quarterly Report on Form 10-Q may not sum due to rounding. Percentages have been calculated using unrounded amounts.
Business Segment Information
The following table represents the significant segment expenses regularly provided to the CEO:
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
Research(a) | $ | $ | |||||||||||||||||||||
Drug Development(b) | |||||||||||||||||||||||
Other(c) | |||||||||||||||||||||||
Research and development | $ | $ | |||||||||||||||||||||
(a) Includes costs to support the discovery and development of new molecular entities through pre-clinical studies.
(b) Includes costs to support clinical development of potential new products, including expansion of indications for existing products through Phase I, Phase II and Phase III clinical studies.
(c) Includes costs to support manufacturing development of pre-approved products, medical support of marketed products, IPRD impairment charges and proportionate allocations of enterprise-wide costs including facilities, information technology, and other appropriate costs.
Use of Estimates and Judgments
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining accounting for acquisitions; impairments of intangible assets; charge-backs, cash discounts, sales rebates, returns and other adjustments; legal contingencies; and income taxes. Actual results may differ from estimates.
6
Recently Adopted Accounting Standards
Derivatives, Hedging and Revenue from Contracts with Customers
In September 2025, the FASB issued amended guidance to refine the scope of derivative accounting and clarify the accounting for share-based noncash consideration from a customer in a revenue contract. Among other provisions, the amendment excludes from derivative accounting non-exchange-traded contracts with underlyings that are based on operations or activities specific to one of the parties in the contract. BMS adopted the new guidance prospectively, beginning on January 1, 2026. The adoption of this guidance did not have an impact on the Company's consolidated financial statements for prior transactions; however, the impact in subsequent periods will be dependent upon the nature of future business development activities.
Recently Issued Accounting Standards Not Yet Adopted
Internal-Use Software
In September 2025, the FASB issued amended guidance on internal-use software. The guidance clarifies disclosure requirements and establishes new capitalization criteria based on management's authorization and funding commitment as well as the probability that a project will be completed and used for its intended function. The amended guidance is effective for annual periods beginning after December 15, 2027 and interim periods within those annual periods. Early adoption is permitted. The Company is assessing the potential impact of the amended standard.
Disaggregation of Income Statement Expenses
In November 2024, the FASB issued guidance on income statement disclosures. The guidance aims to provide enhanced disclosures of income statement expenses to improve transparency and provide financial statement users with more detailed information about the nature, amount and timing of expenses impacting financial performance. The new guidance is effective for annual periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted.
Note 2. REVENUE
The following table summarizes the disaggregation of revenue by nature:
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
| Net product sales | $ | $ | |||||||||||||||||||||
| Alliance revenues | |||||||||||||||||||||||
| Other revenues | |||||||||||||||||||||||
| Total Revenues | $ | $ | |||||||||||||||||||||
The following table summarizes GTN adjustments:
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
| Gross product sales | $ | $ | |||||||||||||||||||||
GTN adjustments(a) | |||||||||||||||||||||||
| Charge-backs and cash discounts | ( | ( | |||||||||||||||||||||
| Medicaid and Medicare rebates | ( | ( | |||||||||||||||||||||
| Other rebates, returns, discounts and adjustments | ( | ( | |||||||||||||||||||||
Total GTN adjustments(b) | ( | ( | |||||||||||||||||||||
| Net product sales | $ | $ | |||||||||||||||||||||
(b) Includes U.S. GTN adjustments of $4.8 billion and $8.2 billion for the three months ended March 31, 2026 and 2025, respectively.
7
The following table summarizes the disaggregation of revenue by product and region:
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
Growth Portfolio | |||||||||||||||||||||||
| Opdivo | $ | $ | |||||||||||||||||||||
Opdivo Qvantig | |||||||||||||||||||||||
| Orencia | |||||||||||||||||||||||
| Yervoy | |||||||||||||||||||||||
| Reblozyl | |||||||||||||||||||||||
Breyanzi | |||||||||||||||||||||||
| Opdualag | |||||||||||||||||||||||
Camzyos | |||||||||||||||||||||||
| Zeposia | |||||||||||||||||||||||
| Sotyktu | |||||||||||||||||||||||
Krazati | |||||||||||||||||||||||
Cobenfy | |||||||||||||||||||||||
Other Growth products(a) | |||||||||||||||||||||||
Total Growth Portfolio | |||||||||||||||||||||||
Legacy Portfolio | |||||||||||||||||||||||
| Eliquis | |||||||||||||||||||||||
| Revlimid | |||||||||||||||||||||||
| Pomalyst/Imnovid | |||||||||||||||||||||||
| Sprycel | |||||||||||||||||||||||
| Abraxane | |||||||||||||||||||||||
Other Legacy products(b) | |||||||||||||||||||||||
Total Legacy Portfolio | |||||||||||||||||||||||
Other revenue(c) | ( | ||||||||||||||||||||||
| Total Revenues | $ | $ | |||||||||||||||||||||
| United States | $ | $ | |||||||||||||||||||||
International | |||||||||||||||||||||||
Other(d) | |||||||||||||||||||||||
| Total Revenues | $ | $ | |||||||||||||||||||||
(a) Includes Abecma, Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues, including royalties received from Merck on Winrevair*.
(b) Includes other mature brands.
(c) Includes revenue hedging activities in 2026.
(d) Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations, including royalties received from Merck on Winrevair*.
Revenue recognized from performance obligations satisfied in prior periods was $221 million and $444 million for the three months ended March 31, 2026 and 2025, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales.
8
Note 3. ALLIANCES
BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. BMS refers to these collaborations as alliances, and its partners as alliance partners.
Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
| Revenues from alliances: | |||||||||||||||||||||||
| Net product sales | $ | $ | |||||||||||||||||||||
| Alliance revenues | |||||||||||||||||||||||
| Total alliance revenues | $ | $ | |||||||||||||||||||||
| Payments to/(from) alliance partners: | |||||||||||||||||||||||
| Cost of products sold | $ | $ | |||||||||||||||||||||
Selling, general and administrative | ( | ( | |||||||||||||||||||||
| Research and development | |||||||||||||||||||||||
| Other (income)/expense, net | ( | ( | |||||||||||||||||||||
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
| Selected alliance balance sheet information: | |||||||||||
| Receivables – from alliance partners | $ | $ | |||||||||
| Accounts payable – to alliance partners | |||||||||||
Deferred income – from alliances(a) | |||||||||||
Note 4. ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS
Divestitures
The following table summarizes the financial impact of divestitures including royalties, which is included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses).
| Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
| Net Proceeds | Divestiture (Gains)/Losses | Royalty Income | |||||||||||||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||||||||
Diabetes business - royalties | $ | $ | $ | $ | $ | $ | ( | ||||||||||||||||||||||||||||
| Mature products and other | ( | ( | |||||||||||||||||||||||||||||||||
| Total | $ | $ | $ | ( | $ | ( | $ | $ | ( | ||||||||||||||||||||||||||
Diabetes Business
As part of the BMS diabetes termination agreement with AstraZeneca, BMS received royalty payments of 14 % in 2025 based on net sales. Royalty payments under this agreement terminated as of December 31, 2025.
9
Licensing and Other Arrangements
The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, upfront licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net.
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
Keytruda* royalties | $ | ( | $ | ( | |||||||||||||||||||
Tecentriq* royalties | ( | ( | |||||||||||||||||||||
| Contingent milestone income | ( | ||||||||||||||||||||||
| Amortization of deferred income | ( | ( | |||||||||||||||||||||
Other royalties and licensing income | ( | ( | |||||||||||||||||||||
| Royalty and licensing income | $ | ( | $ | ( | |||||||||||||||||||
Keytruda* Patent License Agreement
BMS and Ono are parties to a global patent license agreement with Merck related to Merck's PD-1 antibody Keytruda*. Under the agreement, Merck is obligated to pay 2.5 % royalties on global sales of Keytruda* from January 1, 2024 through December 31, 2026. The companies also granted certain rights to each other under their respective patent portfolios pertaining to PD-1. Payments and royalties are shared between BMS and Ono on a 75 /25 percent allocation, respectively, after adjusting for each party's legal fees.
Tecentriq* Patent License Agreement
BMS and Ono are parties to a global patent license agreement with Roche related to Tecentriq*, Roche’s anti-PD-L1 antibody. Under the agreement, Roche is obligated to pay single-digit royalties on worldwide net sales of Tecentriq* through December 31, 2026. The royalties are shared between BMS and Ono consistent with existing agreements.
In-license and other arrangements
Reblozyl and Winrevair* License Agreements
BMS and Merck are parties to a global licensing agreement pursuant to which BMS licenses Reblozyl from Merck. Under the agreement, BMS is responsible for the development and commercialization of Reblozyl. BMS pays tiered royalties to Merck ranging from 20 % to 24 % of net sales, which are recorded in Cost of products sold. Royalty expense incurred by BMS under the agreement was $124 million and $106 million during the three months ended March 31, 2026 and 2025, respectively.
Additionally, BMS and Merck are parties to a separate global licensing agreement pursuant to which Merck licenses Winrevair*, a novel activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension, from BMS. Under the agreement, Merck is responsible for the development and commercialization of Winrevair*. BMS receives royalties from Merck equal to 22 % of net sales, which are recorded in Other revenues. Royalties earned by BMS under the agreement were $124 million and $42 million during the three months ended March 31, 2026 and 2025, respectively.
Note 5. OTHER (INCOME)/EXPENSE, NET
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
Interest expense | $ | $ | |||||||||||||||||||||
Royalty income - divestitures (Note 4) | ( | ||||||||||||||||||||||
| Royalty and licensing income (Note 4) | ( | ( | |||||||||||||||||||||
Investment income | ( | ( | |||||||||||||||||||||
| Provision for restructuring (Note 6) | |||||||||||||||||||||||
Litigation and other settlements | |||||||||||||||||||||||
Equity investment (gains)/losses, net (Note 9) | ( | ||||||||||||||||||||||
| Integration expenses (Note 6) | |||||||||||||||||||||||
Other | |||||||||||||||||||||||
Other (income)/expense, net | $ | $ | |||||||||||||||||||||
10
Note 6. RESTRUCTURING
2023 Restructuring Plan
In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s strategy to invest in key priorities. These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing BMS's commercial operating model, and (iii) establishing a more responsive manufacturing network. As a result, total charges for the 2023 Restructuring Plan are expected to be approximately $2.5 billion through 2027, with $1.8 billion incurred to date. The remaining charges consist primarily of site exit costs, including impairment and accelerated depreciation of property, plant and equipment, and employee termination costs.
Other Acquisition Plans
Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from acquisitions. For these plans, the remaining charges of approximately $65 million consist primarily of IT system integration costs, employee termination costs, and to a lesser extent, site exit costs, including impairment and accelerated depreciation of property, plant and equipment.
The following provides the charges related to restructuring initiatives by type of cost:
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
| 2023 Restructuring Plan | $ | ( | $ | ||||||||||||||||||||
Other Acquisition Plans | |||||||||||||||||||||||
| Total charges | $ | $ | |||||||||||||||||||||
| Employee termination costs | $ | ( | $ | ||||||||||||||||||||
| Other termination costs | |||||||||||||||||||||||
| Provision for restructuring | |||||||||||||||||||||||
| Integration expenses | |||||||||||||||||||||||
| Accelerated depreciation | |||||||||||||||||||||||
Asset impairments | |||||||||||||||||||||||
| Other shutdown costs, net | ( | ( | |||||||||||||||||||||
| Total charges | $ | $ | |||||||||||||||||||||
| Cost of products sold | $ | $ | |||||||||||||||||||||
| Selling, general and administrative | |||||||||||||||||||||||
| Research and development | |||||||||||||||||||||||
| Other (income)/expense, net | ( | ||||||||||||||||||||||
| Total charges | $ | $ | |||||||||||||||||||||
The following summarizes the charges and spending related to restructuring plan activities:
| Three Months Ended March 31, | |||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||
| Beginning balance | $ | $ | |||||||||
| Provision for restructuring | |||||||||||
| Payments | ( | ( | |||||||||
| Foreign currency translation and other | ( | ||||||||||
| Ending balance | $ | $ | |||||||||
11
Note 7. INCOME TAXES
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
Earnings/(Loss) before income taxes | $ | $ | |||||||||||||||||||||
Income tax provision | |||||||||||||||||||||||
| Effective tax rate | % | % | |||||||||||||||||||||
Provision for income taxes in interim periods is determined based on the estimated annual effective tax rates and the tax impact of discrete items that are reflected immediately. The increase in the effective tax rate was primarily driven by jurisdictional earnings mix, partially offset by the impact of certain discrete adjustments.
Additional changes to the effective tax rate may occur in future periods due to various reasons, including changes to the estimated pretax earnings mix and tax reserves and revised interpretations or changes to the tax code.
During the three months ended March 31, 2026 and 2025, income tax payments were $239 million and $235 million.
BMS is currently under examination by a number of tax authorities that proposed or are considering proposing material adjustments to tax positions for issues such as transfer pricing, certain tax credits and the deductibility of certain expenses. As previously disclosed, BMS received several notices of proposed adjustments from the IRS related to transfer pricing and other tax issues for the 2008 to 2012 tax years. BMS disagrees with the IRS's positions and continues to work cooperatively with the IRS to resolve these issues. In 2022, BMS entered the IRS administrative appeals process to resolve these matters, and that appeals process is ongoing. Timing of the final resolution of these complex matters is uncertain and could have a material impact on BMS's consolidated financial statements. BMS believes that it has adequately provided for all open tax years by jurisdiction.
Note 8. EARNINGS/(LOSS) PER SHARE
| Three Months Ended March 31, | |||||||||||||||||||||||
| Amounts in millions, except per share data | 2026 | 2025 | |||||||||||||||||||||
Net earnings/(loss) attributable to BMS | $ | $ | |||||||||||||||||||||
| Weighted-average common shares outstanding – basic | |||||||||||||||||||||||
| Incremental shares attributable to share-based compensation plans | |||||||||||||||||||||||
| Weighted-average common shares outstanding – diluted | |||||||||||||||||||||||
Earnings/(Loss) per common share | |||||||||||||||||||||||
| Basic | $ | $ | |||||||||||||||||||||
| Diluted | |||||||||||||||||||||||
12
Note 9. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
| March 31, 2026 | December 31, 2025 | ||||||||||||||||||||||||||||||||||
| Dollars in millions | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3 | |||||||||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||||||||||||||
| Money market and other securities | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||
| Marketable debt securities | |||||||||||||||||||||||||||||||||||
| Certificates of deposit | |||||||||||||||||||||||||||||||||||
| Corporate debt securities | |||||||||||||||||||||||||||||||||||
| U.S. Treasury securities | |||||||||||||||||||||||||||||||||||
| Derivative assets | |||||||||||||||||||||||||||||||||||
Equity investments | |||||||||||||||||||||||||||||||||||
| Derivative liabilities | |||||||||||||||||||||||||||||||||||
| Contingent consideration liability | |||||||||||||||||||||||||||||||||||
Contingent value rights(a) | |||||||||||||||||||||||||||||||||||
(a) Includes the fair value of contingent value rights associated with the Mirati acquisition. The fair value of contingent value rights was estimated using a probability-weighted expected return method.
As further described in "Item 8. Financial Statements and Supplementary Data—Note 9. Financial Instruments and Fair Value Measurements" in the Company's 2025 Form 10-K, the Company's fair value estimates use inputs that are either (1) quoted prices for identical assets or liabilities in active markets (Level 1 inputs); (2) observable prices for similar assets or liabilities in active markets or for identical or similar assets or liabilities in markets that are not active (Level 2 inputs); or (3) unobservable inputs (Level 3 inputs). The fair value of Level 2 equity investments is adjusted for characteristics specific to the security and is not adjusted for contractual sale restrictions. Equity investments subject to contractual sale restrictions were not material as of March 31, 2026 and December 31, 2025.
Marketable Debt Securities
The amortized cost for marketable debt securities approximates its fair value and these securities mature within five years
13
Equity Investments
The following summarizes the carrying amount of equity investments:
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
Equity investments with RDFV | $ | $ | |||||||||
Equity investments without RDFV | |||||||||||
| Limited partnerships and other investments | |||||||||||
| Total equity investments | $ | $ | |||||||||
The following summarizes the activity related to equity investments. Changes in fair value of equity investments are included in Other (income)/expense, net.
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
Equity investments with RDFV | |||||||||||||||||||||||
| Net (gains)/losses recognized | $ | ( | $ | ||||||||||||||||||||
| Less: net (gains)/losses recognized on investments sold | ( | ||||||||||||||||||||||
| Net unrealized (gains)/losses recognized on investments still held | ( | ||||||||||||||||||||||
Equity investments without RDFV | |||||||||||||||||||||||
Upward adjustments | ( | ||||||||||||||||||||||
| Net realized (gains)/losses recognized on investments sold | |||||||||||||||||||||||
Impairments and downward adjustments | |||||||||||||||||||||||
| Limited partnerships and other investments | |||||||||||||||||||||||
Equity in net (income)/loss of affiliates and other adjustments | ( | ||||||||||||||||||||||
Total equity investment (gains)/losses | $ | ( | $ | ||||||||||||||||||||
Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without RDFV still held as of March 31, 2026 were $365 million and $238 million, respectively.
Qualifying Hedges and Non-Qualifying Derivatives
Cash Flow Hedges
BMS enters into foreign currency forward and purchased local currency put option contracts (foreign currency exchange contracts) to hedge certain forecasted intercompany inventory sales, third party sales and certain other foreign currency transactions. The objective of these foreign currency exchange contracts is to reduce variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro and Japanese yen. The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the consolidated balance sheets. Changes in fair value for these foreign currency exchange contracts, which are designated as cash flow hedges, are temporarily recorded in AOCL and reclassified to net earnings when the hedged item affects earnings (typically within the next 24 months). Beginning in 2026, gains and losses on foreign currency cash flow hedges related to intercompany inventory sales, which were previously presented in Cost of products sold, are now presented in Alliance and other revenues due to a change in the nature of the hedged item. As of March 31, 2026, assuming market rates remain constant through contract maturities, BMS expects to reclassify pre-tax losses of $14 million into Alliance and other revenues for the Company's foreign currency exchange contracts out of AOCL during the next 12 months. The notional amount of outstanding foreign currency exchange contracts was primarily $4.1 billion for the euro contracts and $1.0 billion for the Japanese yen contracts as of March 31, 2026.
BMS also enters into cross-currency swap contracts to hedge exposure to foreign currency exchange rate risk associated with its long-term debt denominated in euros. These contracts convert interest payments and principal repayment of the long-term debt to U.S. dollars from euros and are designated as cash flow hedges. The unrealized gains and losses on these contracts are reported in AOCL and reclassified to Other (income)/expense, net, in the same periods during which the hedged debt affects earnings. The notional amount of cross-currency swap contracts associated with long-term debt denominated in euros was $584 million as of March 31, 2026.
14
Cash flow hedge accounting is discontinued when the forecasted transaction is no longer probable of occurring within 60 days after the originally forecasted date or when the hedge is no longer effective. Assessments to determine whether derivatives designated as qualifying hedges are highly effective in offsetting changes in the cash flows of hedged items are performed at inception and on a quarterly basis. The earnings impact related to discontinued cash flow hedges and hedge ineffectiveness was not material during all periods presented. Foreign currency exchange contracts not designated as a cash flow hedge offset exposures in certain foreign currency denominated assets, liabilities and earnings. Changes in the fair value of these derivatives are recognized in earnings as they occur.
Net Investment Hedges
Cross-currency swap contracts of $707 million as of March 31, 2026 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offset in derivative asset or liability in the consolidated balance sheets. The notional amount of outstanding cross-currency swap contracts was primarily attributed to the Japanese yen of $362 million and the euro of $345 million as of March 31, 2026. Foreign currency forward contracts and zero-cost collar contracts are also designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. As of March 31, 2026, the notional amounts for both of these contracts were zero.
During the three months ended March 31, 2026 and 2025, the amortization of gains related to the portion of the Company's net investment hedges that was excluded from the assessment of effectiveness was not material.
Fair Value Hedges
Fixed to floating interest rate swap contracts are designated as fair value hedges and used as an interest rate risk management strategy to create an appropriate balance of fixed and floating rate debt. The contracts and underlying debt for the hedged benchmark risk are recorded at fair value. Gains or losses resulting from changes in fair value of the underlying debt attributable to the hedged benchmark interest rate risk are recorded in interest expense with an associated offset to the carrying value of debt. Since the specific terms and notional amount of the swap are intended to align with the debt being hedged, all changes in fair value of the swap are recorded in interest expense with an associated offset to the derivative asset or liability in the consolidated balance sheets. As a result, there was no net impact in earnings. If the underlying swap is terminated prior to maturity, then the fair value adjustment to the underlying debt is amortized as an adjustment to interest expense over the remaining term of the hedged item.
Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating section of the consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in investing activities.
The following table summarizes the fair value and the notional values of outstanding derivatives:
| March 31, 2026 | December 31, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||
Asset(a) | Liability(b) | Asset(a) | Liability(b) | ||||||||||||||||||||||||||||||||||||||||||||
| Dollars in millions | Notional | Fair Value | Notional | Fair Value | Notional | Fair Value | Notional | Fair Value | |||||||||||||||||||||||||||||||||||||||
| Designated as cash flow hedges | |||||||||||||||||||||||||||||||||||||||||||||||
Foreign currency exchange contracts | $ | $ | $ | $ | ( | $ | $ | $ | $ | ( | |||||||||||||||||||||||||||||||||||||
| Cross-currency swap contracts | |||||||||||||||||||||||||||||||||||||||||||||||
| Designated as net investment hedges | |||||||||||||||||||||||||||||||||||||||||||||||
| Cross-currency swap contracts | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||
| Designated as fair value hedges | |||||||||||||||||||||||||||||||||||||||||||||||
| Interest rate swap contracts | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||
| Not designated as hedges | |||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency exchange contracts | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||
Total return swap contracts(c) | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||
(a) Included in Other current assets and Other non-current assets.
(b) Included in Other current liabilities and Other non-current liabilities.
(c) Total return swap contracts hedge changes in fair value of certain deferred compensation liabilities.
15
The following table summarizes the financial statement classification and amount of gains and losses recognized on hedges:
| Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 | |||||||||||||||||||||||||
| Dollars in millions | Gains/(losses) recognized in Alliance and other revenues | (Gains)/losses recognized in Other (income)/expense, net | (Gains)/losses recognized in Cost of products sold | (Gains)/losses recognized in Other (income)/expense, net | ||||||||||||||||||||||
Foreign currency exchange contracts | $ | ( | $ | ( | $ | ( | $ | |||||||||||||||||||
| Cross-currency swap contracts | ( | |||||||||||||||||||||||||
| Interest rate swap contracts | ( | ( | ||||||||||||||||||||||||
Forward interest rate contracts | ( | ( | ||||||||||||||||||||||||
The following table summarizes the effect of derivative and non-derivative instruments designated as hedges in Other comprehensive income/(loss):
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
| Derivatives designated as cash flow hedges | |||||||||||||||||||||||
Foreign currency exchange contracts gains/(losses): | |||||||||||||||||||||||
| Recognized in Other comprehensive income/(loss) | $ | $ | ( | ||||||||||||||||||||
Reclassified to Alliance and other revenues | |||||||||||||||||||||||
Reclassified to Cost of products sold | ( | ||||||||||||||||||||||
| Cross-currency swap contracts gains/(losses): | |||||||||||||||||||||||
| Recognized in Other comprehensive income/(loss) | ( | ||||||||||||||||||||||
| Reclassified to Other (income)/expense, net | ( | ||||||||||||||||||||||
| Forward interest rate contract gains/(losses): | |||||||||||||||||||||||
| Reclassified to Other (income)/expense, net | ( | ( | |||||||||||||||||||||
| Derivatives designated as net investment hedges | |||||||||||||||||||||||
| Cross-currency swap contracts gains/(losses): | |||||||||||||||||||||||
| Recognized in Other comprehensive income/(loss) | ( | ||||||||||||||||||||||
Foreign currency exchange contracts gains/(losses): | |||||||||||||||||||||||
| Recognized in Other comprehensive income/(loss) | ( | ( | |||||||||||||||||||||
Note 10. FINANCING ARRANGEMENTS
Short-term debt obligations include:
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
Non-U.S. short-term financing obligations | $ | $ | |||||||||
| Current portion of Long-term debt | |||||||||||
Short-term debt obligations | $ | $ | |||||||||
Under its commercial paper program, BMS may issue a maximum of $5.0 billion of unsecured notes with maturities of not more than 365 days from the date of issuance.
16
Long-term debt and the current portion of Long-term debt include:
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
| Principal value | $ | $ | |||||||||
| Adjustments to principal value: | |||||||||||
| Fair value of interest rate swap contracts | |||||||||||
| Unamortized basis adjustment from swap terminations | |||||||||||
| Unamortized bond discounts and issuance costs | ( | ( | |||||||||
| Unamortized purchase price adjustments of Celgene debt | |||||||||||
| Total | $ | $ | |||||||||
| Current portion of Long-term debt | $ | $ | |||||||||
| Long-term debt | |||||||||||
| Total | $ | $ | |||||||||
The fair value of Long-term debt, including the current portion, was $40.2 billion as of March 31, 2026 and $41.5 billion as of December 31, 2025 valued using Level 2 inputs, which are based upon the quoted market prices for the same or similar debt instruments. The fair value of Short-term debt obligations approximates the carrying value due to the short maturities of the debt instruments.
During the three months ended March 31, 2026, $500 million of floating rate notes matured and were repaid.
Interest payments were $473 million and $624 million for the three months ended March 31, 2026 and 2025, respectively, net of amounts related to interest rate swap contracts.
Credit Facilities
As of March 31, 2026 and December 31, 2025, BMS had a five-year $5.0 billion revolving credit facility, which is extendable annually by one year No
Note 11. RECEIVABLES
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
| Trade receivables | $ | $ | |||||||||
Less charge-backs and cash discounts | ( | ( | |||||||||
Less allowance for expected credit loss | ( | ( | |||||||||
| Net trade receivables | |||||||||||
| Alliance, royalties, VAT and other | |||||||||||
| Receivables | $ | $ | |||||||||
Non-U.S. receivables sold on a nonrecourse basis were $37 million and $75 million for the three months ended March 31, 2026 and 2025, respectively. Receivables from the three largest customers in the U.S. represented 70 % and 75 % of total trade receivables as of March 31, 2026 and December 31, 2025, respectively.
17
Note 12. INVENTORIES
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
| Finished goods | $ | $ | |||||||||
| Work in process | |||||||||||
| Raw and packaging materials | |||||||||||
| Total inventories | $ | $ | |||||||||
| Inventories | $ | $ | |||||||||
| Other non-current assets | |||||||||||
Note 13. PROPERTY, PLANT AND EQUIPMENT
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
| Land | $ | $ | |||||||||
| Buildings | |||||||||||
| Machinery, equipment and fixtures | |||||||||||
| Construction in progress | |||||||||||
| Gross property, plant and equipment | |||||||||||
| Less accumulated depreciation | ( | ( | |||||||||
| Property, plant and equipment | $ | $ | |||||||||
Depreciation expense was $139 million and $165 million for the three months ended March 31, 2026 and 2025, respectively.
Note 14. GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill
The changes in the carrying amounts in Goodwill were as follows:
| Dollars in millions | |||||||||||
Balance at December 31, 2025 | $ | ||||||||||
| Currency translation and other adjustments | ( | ||||||||||
Balance at March 31, 2026 | $ | ||||||||||
Other Intangible Assets
Other intangible assets consisted of the following:
| Estimated Useful Lives | March 31, 2026 | December 31, 2025 | |||||||||||||||||||||||||||||||||||||||
Dollars in millions | Gross carrying amounts | Accumulated amortization | Other intangible assets, net | Gross carrying amounts | Accumulated amortization | Other intangible assets, net | |||||||||||||||||||||||||||||||||||
| R&D technology | $ | $ | ( | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||
| Acquired marketed product rights | ( | ( | |||||||||||||||||||||||||||||||||||||||
| Capitalized software | ( | ( | |||||||||||||||||||||||||||||||||||||||
| IPRD | — | — | |||||||||||||||||||||||||||||||||||||||
| Total | $ | $ | ( | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||
Amortization expense of Other intangible assets was $472 million and $863 million during the three months ended March 31, 2026 and 2025, respectively.
During the three months ended March 31, 2026, $410 million of IPRD impairment charges were recorded in Research and development expense. The charges represent a partial write-down of a radiopharmaceutical asset driven by an indication realignment within our portfolio as well as a partial write-down of a separate oncology asset based on recent clinical results.
18
Note 15. SUPPLEMENTAL FINANCIAL INFORMATION
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
| Income taxes | $ | $ | |||||||||
| Research and development | |||||||||||
| Contract assets | |||||||||||
| Other | |||||||||||
| Other current assets | $ | $ | |||||||||
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
| Equity investments (Note 9) | $ | $ | |||||||||
Operating leases | |||||||||||
Inventories (Note 12) | |||||||||||
| Pension and postretirement | |||||||||||
| Research and development | |||||||||||
| Other | |||||||||||
| Other non-current assets | $ | $ | |||||||||
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
| Rebates and discounts | $ | $ | |||||||||
| Income taxes | |||||||||||
| Employee compensation and benefits | |||||||||||
| Research and development | |||||||||||
| Dividends | |||||||||||
| Interest | |||||||||||
| Royalties | |||||||||||
| Operating leases | |||||||||||
| Other | |||||||||||
| Other current liabilities | $ | $ | |||||||||
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
| Income taxes | $ | $ | |||||||||
| Pension and postretirement | |||||||||||
Operating leases | |||||||||||
| Deferred income | |||||||||||
| Deferred compensation | |||||||||||
Contingent value rights (Note 9) | |||||||||||
| Other | |||||||||||
| Other non-current liabilities | $ | $ | |||||||||
19
Note 16. EQUITY
The following table summarizes changes in equity during the three months ended March 31, 2026:
| Common Stock | Capital in Excess of Par Value of Stock | Accumulated Other Comprehensive Loss | Retained Earnings | Treasury Stock | Noncontrolling Interest | ||||||||||||||||||||||||||||||||||||||||||
| Dollars and shares in millions | Shares | Par Value | Shares | Cost | |||||||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2025 | $ | $ | $ | ( | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||
| Net earnings/(loss) | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Other comprehensive income/(loss) | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
Cash dividends declared $ | — | — | — | — | ( | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Stock compensation | — | — | ( | — | — | ( | — | ||||||||||||||||||||||||||||||||||||||||
Balance at March 31, 2026 | $ | $ | $ | ( | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||
The following table summarizes changes in equity during the three months ended March 31, 2025:
| Common Stock | Capital in Excess of Par Value of Stock | Accumulated Other Comprehensive Loss | Retained Earnings | Treasury Stock | Noncontrolling Interest | ||||||||||||||||||||||||||||||||||||||||||
| Dollars and shares in millions | Shares | Par Value | Shares | Cost | |||||||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2024 | $ | $ | $ | ( | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||
| Net earnings/(loss) | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Other comprehensive income/(loss) | — | — | — | ( | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
Cash dividends declared $ | — | — | — | — | ( | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Stock compensation | — | — | ( | — | — | ( | — | ||||||||||||||||||||||||||||||||||||||||
Balance at March 31, 2025 | $ | $ | $ | ( | $ | $ | ( | $ | |||||||||||||||||||||||||||||||||||||||
The components of Other comprehensive income/(loss) were as follows:
| Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 | ||||||||||||||||||||||||||||||||||
| Dollars in millions | Pretax | Tax | After Tax | Pretax | Tax | After Tax | |||||||||||||||||||||||||||||
Derivatives qualifying as cash flow hedges: | |||||||||||||||||||||||||||||||||||
Recognized in other comprehensive income/(loss) | $ | $ | ( | $ | $ | ( | $ | $ | ( | ||||||||||||||||||||||||||
Reclassified to net earnings(a) | ( | ( | ( | ||||||||||||||||||||||||||||||||
| Derivatives qualifying as cash flow hedges | ( | ( | ( | ||||||||||||||||||||||||||||||||
| Pension and postretirement benefits | |||||||||||||||||||||||||||||||||||
| Actuarial gains/(losses) | |||||||||||||||||||||||||||||||||||
Amortization(b) | ( | ( | |||||||||||||||||||||||||||||||||
Settlements(b) | ( | ||||||||||||||||||||||||||||||||||
| Pension and postretirement benefits | ( | ( | |||||||||||||||||||||||||||||||||
Marketable debt securities | |||||||||||||||||||||||||||||||||||
| Unrealized gains/(losses) | ( | ( | |||||||||||||||||||||||||||||||||
| Foreign currency translation | ( | ||||||||||||||||||||||||||||||||||
| Other comprehensive income/(loss) | $ | $ | ( | $ | $ | ( | $ | $ | ( | ||||||||||||||||||||||||||
(a)Included in Alliance and other revenues, Cost of products sold and Other (income)/expense, net. Refer to "—Note 9. Financial Instruments and Fair Value Measurements" for further information.
(b)Included in Other (income)/expense, net.
20
The accumulated balances related to each component of Other comprehensive income/(loss), net of taxes, were as follows:
| Dollars in millions | March 31, 2026 | December 31, 2025 | |||||||||
| Derivatives qualifying as cash flow hedges | $ | $ | |||||||||
| Pension and postretirement benefits | ( | ( | |||||||||
| Marketable debt securities | |||||||||||
Foreign currency translation(a) | ( | ( | |||||||||
| Accumulated other comprehensive loss | $ | ( | $ | ( | |||||||
(a)Includes net investment hedge gains of $112 million and $105 million as of March 31, 2026 and December 31, 2025, respectively.
Note 17. EMPLOYEE STOCK BENEFIT PLANS
Stock-based compensation expense was as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
| Cost of products sold | $ | $ | |||||||||||||||||||||
Selling, general and administrative | |||||||||||||||||||||||
| Research and development | |||||||||||||||||||||||
Total stock-based compensation expense | $ | $ | |||||||||||||||||||||
| Income tax benefit | $ | $ | |||||||||||||||||||||
The number of units granted and the weighted-average fair value on the grant date for the three months ended March 31, 2026 were as follows:
| Units in millions | Units | Weighted-Average Fair Value | |||||||||
| Restricted stock units | $ | ||||||||||
| Market share units | $ | ||||||||||
| Performance share units | $ | ||||||||||
| Dollars in millions | Restricted Stock Units | Market Share Units | Performance Share Units | ||||||||||||||||||||
| Unrecognized compensation cost | $ | $ | $ | ||||||||||||||||||||
| Expected weighted-average period in years of compensation cost to be recognized | |||||||||||||||||||||||
Note 18. LEGAL PROCEEDINGS AND CONTINGENCIES
BMS and certain of its subsidiaries are involved in various lawsuits, claims, government investigations, and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, partners, suppliers, service providers, licensees, licensors, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability, and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that BMS believes could become significant or material are described below.
BMS is vigorously defending against the legal proceedings in which it is named as a defendant and believes it has substantial claims and/or defenses in each matter. While the outcomes of these proceedings and other contingencies BMS is subject to are inherently unpredictable and uncertain, BMS does not believe that any of these matters will have a material adverse effect on BMS’ financial position or liquidity, though they could possibly be material to the Company's consolidated results of operations in any one accounting period. There can be no assurance that there will not be an increase in the scope of one or more of the matters described below or that any other or future lawsuits, claims, government investigations, or other legal proceedings will not be material to BMS’s financial position, results of operations, or cash flows for a particular period. Furthermore, failure to successfully enforce BMS’s patent rights would likely result in substantial decreases in the respective product revenues from generic competition.
21
Contingency accruals are recognized when it is probable that a liability will be incurred and the amount of the related loss can be reasonably estimated. If BMS is unable to assess the outcome of a matter or estimate the possible loss or range of losses that could potentially result from such matter, a liability is not recorded. Developments in legal proceedings and other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS’s tax contingencies, see " — Note 7. Income Taxes."
INTELLECTUAL PROPERTY
Eliquis - U.S.
In November 2025, BMS received a Notice Letter from Azurity Pharmaceuticals, Inc. (“Azurity”) notifying BMS that Azurity had filed a 505(b)(2) application containing a paragraph IV certification seeking approval to market apixaban products in the U.S. and challenging a formulation patent listed in the Orange Book for Eliquis but not the composition of matter patent. In response, BMS and Pfizer initiated a patent infringement action against Azurity in the U.S. District Court for the District of Delaware.
Eliquis - Europe
BMS is involved in litigations throughout Europe against companies seeking to launch generic apixaban products prior to the expiration of the composition-of-matter patent for Eliquis and its associated SPCs. Litigations are pending or have concluded in Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Greece, Hungary, Ireland, Italy, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland, and the UK.
To date, courts in these jurisdictions have rendered the following decisions:
•The court made a final negative decision in the UK, and generics are now on the market there.
•The courts made final positive decisions in Norway, Spain, Sweden, and Switzerland. In addition, the courts made initial positive decisions in France, Belgium, Croatia, and the Netherlands which are now final, following settlement.
•The courts made initial negative decisions in Finland, Ireland, and Slovakia. In Slovakia, an appeal is pending. In Finland and Ireland, the appeals court overturned the initial decisions and remanded the cases to the lower court. The case in Ireland is now settled.
•The courts made initial positive decisions in Denmark, the Czech Republic, Greece, and Portugal. In Denmark and Greece, appeals are pending. In Portugal, the positive decision was upheld on appeal. In the Czech Republic, the appeals court remanded the case to the lower court, which confirmed the positive decision.
One or more generics have entered the market in Poland while proceedings are pending. Additional generic manufacturers may seek to market generic apixaban products in these or additional countries in Europe prior to the expiration of the Company's patents, which may lead to additional infringement and invalidity actions in Europe.
PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION
Plavix* Texas Litigation
In November 2025, BMS and certain Sanofi entities were named defendants in a Texas state court action in Harrison County, Texas brought by the attorney general of Texas (the “Texas AG") and by a qui tam relator on behalf of the State of Texas relating to the labeling, sales, and promotion of Plavix*. The case was removed to the U.S. District Court for the Eastern District of Texas but was remanded to state court in Harrison County in March 2026. Also in November 2025, BMS and certain Sanofi entities sued the Texas AG in state court in Travis County, Texas to enjoin the Texas AG's lawsuit, although in April 2026 the Travis County court abated that lawsuit pending disposition of the Harrison County case. No trial dates have been scheduled in either case.
SECURITIES LITIGATION
Celgene Securities Litigations
Beginning in March 2018, two putative class actions were filed against Celgene and certain of its officers and employees in the U.S. District Court for the District of New Jersey (the “Celgene Securities Class Action”). The complaints alleged that the defendants violated federal securities laws. The district court consolidated the two actions. In December 2019, the district court denied in part and granted in part defendants’ motion to dismiss. In November 2020, the district court certified a class of Celgene common stock purchasers between April 27, 2017 through April 28, 2018. Following discovery, defendants moved for summary judgment, which the district court granted in part and denied in part. In September 2025, the parties reached a settlement in principle to resolve the Celgene Securities Class Action. The court granted preliminary approval of the settlement in December 2025, with a final approval hearing scheduled for May 2026.
22
Certain entities filed individual actions in the U.S. District Court for the District of New Jersey asserting largely the same allegations as the Celgene Securities Class Action. These actions were consolidated for pre-trial proceedings. Defendants moved for partial summary judgment in these consolidated actions. In August 2025, the court issued a partial summary judgment ruling, dismissing certain statements, although portions of the defendants’ summary judgment motion related to certain other alleged misstatements remained pending before the court. In January 2026, the parties reached a settlement to resolve the individual actions, and those actions have been closed by the court.
Contingent Value Rights Litigations
In June 2021, an action was filed against BMS in the U.S. District Court for the Southern District of New York asserting claims of alleged breaches of a Contingent Value Rights Agreement (“CVR Agreement”) entered into in connection with the closing of BMS’s acquisition of Celgene in November 2019. An entity claiming to be the successor trustee under the CVR Agreement alleged that BMS breached the CVR Agreement by allegedly failing to use “diligent efforts” to obtain FDA approval of liso-cel (Breyanzi) before a contractual milestone date, thereby allegedly avoiding a $6.4 billion potential obligation to holders of the contingent value rights governed by the CVR Agreement and by allegedly failing to permit inspection of records in response to a request by the alleged successor trustee. The plaintiff sought damages in an amount to be determined at trial and other relief, including interest and attorneys’ fees. BMS disputes the allegations. BMS filed a motion to dismiss the alleged successor trustee’s complaint for failure to state a claim upon which relief can be granted, which was denied in June 2022. In February 2024, BMS filed a motion to dismiss the complaint for lack of subject matter jurisdiction. In September 2024, the court granted BMS’s motion and dismissed the lawsuit for lack of subject matter jurisdiction without prejudice to the refiling of a new lawsuit by a properly appointed trustee. The plaintiff has appealed, and BMS has cross-appealed from the denial of its first motion to dismiss.
In November 2024, the same entity claiming to be successor trustee filed a new lawsuit against BMS making similar allegations to the previously dismissed case and attempting to remedy its jurisdictional deficiency. The plaintiff’s new complaint also named the original CVR Agreement Trustee and sought a judgment that plaintiff is Trustee. In February 2025, plaintiff filed an amended complaint. In March 2025, BMS filed a motion to dismiss the amended complaint for lack of subject matter jurisdiction and failure to state a claim. In December 2025, the court denied that motion in substantial part, finding the plaintiff to be the successor trustee, but dismissed two of the five claims asserted in the amended complaint. BMS has filed a motion for reconsideration or, in the alternative, certification for immediate appeal. In the same case, the original trustee (which also has been named a defendant) filed putative crossclaims against BMS in the event that it is later found to be the trustee. In December 2025, BMS filed a motion to dismiss the crossclaims for lack of subject matter jurisdiction or failure to state a claim.
In November 2021, an alleged Celgene stockholder filed a complaint in the Superior Court of New Jersey, Union County, asserting claims on behalf of two separate putative classes, one of acquirers of CVRs and one of acquirers of BMS common stock, for violations of securities laws. In June 2024, the court granted defendants’ motion to dismiss the complaint in its entirety without prejudice to file an amended complaint. The plaintiff filed an amended complaint which was dismissed with prejudice in February 2025. The plaintiff has appealed the dismissal.
In July 2025, an individual beneficial owner of CVRs filed a lawsuit against BMS in the Southern District of New York making similar allegations to the previously dismissed case. BMS moved to dismiss the complaint in September 2025.
No trial dates have been scheduled in any of the above CVR Litigations.
OTHER LITIGATION
IRA Litigation
On June 16, 2023, BMS filed a lawsuit against HHS and the Centers for Medicare & Medicaid Services, et al., challenging the constitutionality of the drug-pricing program in the IRA. That program requires pharmaceutical companies, like BMS, under the threat of significant penalties, to sell certain of their medicines at government-dictated prices. In April 2024, the court denied BMS’s motion for summary judgment and granted the government’s cross-motion for summary judgment. BMS appealed to the United States Court of Appeals for the Third Circuit. In September 2025, the Third Circuit affirmed the lower court’s decision. In December 2025, BMS filed a petition for certiorari at the Supreme Court of the United States, seeking review of the Third Circuit’s decision.
340B Litigation
On November 26, 2024, BMS filed a lawsuit against Carole Johnson, Administrator of Health Resources & Services Administration (“HRSA”) and Xavier Becerra, U.S. Secretary of HHS, challenging HRSA’s determination that BMS could not implement a cash rebate model for the 340B drug pricing program. BMS is seeking a determination that HRSA’s actions violate the Administrative Procedure Act and the United States Constitution. In May 2025, the U.S. District Court for the District of Columbia granted HRSA summary judgment on BMS’s claims. BMS has appealed to the U.S. Court of Appeals for the District of Columbia Circuit, and the Court heard oral argument in November 2025.
23
Thalomid and Revlimid Litigations
Beginning in November 2014, putative class action lawsuits were filed against Celgene in the U.S. District Court for the District of New Jersey alleging that Celgene violated various antitrust, consumer protection, and unfair competition laws in connection with, among other things, activities related to obtaining and litigating certain Revlimid patents. In October 2020, the district court entered a final order approving a class settlement and dismissed the matter. Certain entities—including entities that opted out of the settlement class and others who claim that their suits are not covered by that settlement—have since filed additional suits against Celgene and BMS pursuing similar claims based on related theories, and a subset of plaintiffs brought additional claims related to copay assistance for Thalomid and Revlimid. Those new suits are principally being litigated in the U.S. District Court for the District of New Jersey. The Court dismissed certain of those complaints with leave to amend in June 2024. All plaintiffs filed amended complaints in August 2024. BMS and Celgene have filed motions to dismiss those complaints, which are currently pending.
Related actions are also pending in San Francisco Superior Court and the Philadelphia County Court of Common Pleas. No activity is expected in these cases until disposition of the New Jersey actions. No trial dates have been scheduled.
Pomalyst Antitrust Class Action
Beginning in September 2023, certain entities filed putative class actions against Celgene, BMS, and certain individuals in the U.S. District Court for the Southern District of New York asserting claims under various antitrust, consumer protection, and unjust enrichment laws in connection with activities related to obtaining and litigating certain Pomalyst patents. In March 2025, the court dismissed the complaints against Celgene, BMS and the named individuals. Plaintiffs sought leave to amend their complaints, and in March 2026, the court denied plaintiffs’ motion for leave to amend and entered judgment in favor of the defendants. In April 2026, the plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Second Circuit. In June 2025, an additional plaintiff filed a suit that is substantively identical to the cases described above, and in April 2026, that plaintiff stipulated to dismissal of its claims, subject to its right to appeal.
ENVIRONMENTAL PROCEEDINGS
As previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS's current or former sites or at waste disposal or reprocessing facilities operated by third parties.
CERCLA and Other Remediation Matters
24
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Management’s discussion and analysis of financial condition and results of operations is provided as a supplement to and should be read in conjunction with the consolidated financial statements and related footnotes included elsewhere in this Quarterly Report on Form 10-Q to enhance the understanding of our results of operations, financial condition and cash flows. Certain amounts in this Quarterly Report on Form 10-Q may not sum due to rounding. Percentages have been calculated using unrounded amounts.
EXECUTIVE SUMMARY
Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry. Our focus as a biopharmaceutical company is on discovering, developing and delivering transformational medicines for patients facing serious diseases in areas where we believe that we have an opportunity to make a meaningful difference: oncology, hematology, immunology, cardiovascular, neuroscience and other areas where we can also create long-term value. Our priorities are to focus on transformational medicines where we have a competitive advantage, drive operational excellence and strategically allocate capital for long-term growth and shareholder returns. Our R&D strategy is designed to invest in the most promising science and to consistently execute in a way that translates that science into new medicines with the highest probability of success. To execute this strategy, we focus on three key priorities: science, execution, and value. Additionally, we are driving commercial execution in our key first-in-class and/or best-in-class marketed products, where we continue to expand and see potential for further expansion into the future. For further information on our strategy, see "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations—Executive Summary—Strategy" in our 2025 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document.
During the first quarter of 2026, we made meaningful progress advancing our pipeline, highlighted by: (i) positive interim Phase III results from the SUCCESSOR‑2 study of oral mezigdomide in RRMM, (ii) positive Phase III results from the SCOUT-HCM trial of Camzyos in adolescents with symptomatic oHCM, (iii) positive top‑line results from a Phase II trial for Reblozyl in adults with Alpha (α)-Thalassemia, (iv) positive interim top‑line results from a Phase III trial conducted in China for iza-bren in previously treated unresectable locally advanced or metastatic TNBC, and (v) FDA acceptance of our NDA for iberdomide in combination with standard therapy for patients with RRMM. Additionally, Sotyktu was approved in the U.S. for the treatment of adults with active PsA and Opdivo was approved in the U.S. and EU for cHL.
We remain committed to the strategic allocation of resources and investing in areas that maximize value and drive sustainable growth. As previously announced, our ongoing strategic productivity initiative includes acceleration of the delivery of medicines to patients by evolving and streamlining our enterprise operating model in key areas such as R&D, manufacturing, commercial and other functions. As a result of an expansion in 2025, we expect to realize annual cost savings of approximately $2.0 billion by the end of 2027. The exit costs resulting from these actions are included in our updated 2023 Restructuring Plan.
Financial Highlights
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions, except per share data | 2026 | 2025 | |||||||||||||||||||||
| Total Revenues | $ | 11,489 | $ | 11,201 | |||||||||||||||||||
| Diluted earnings/(loss) per share | |||||||||||||||||||||||
| GAAP | $ | 1.31 | $ | 1.20 | |||||||||||||||||||
| Non-GAAP | 1.58 | 1.80 | |||||||||||||||||||||
Revenues increased 3% during the first quarter of 2026. Demand increased across the Growth Portfolio and for Eliquis, which was partially offset by the impact of generics across the remainder of the Legacy Portfolio. Additionally, revenues were impacted by lower average net selling prices for the Legacy Portfolio and foreign exchange impacts of 2%. Excluding foreign exchange impacts, revenues increased 1%.
The $0.11 increase in GAAP EPS for the first quarter of 2026 was primarily due to the impact of certain specified items, including lower amortization of acquired intangible assets, partially offset by higher IPRD impairment charges in 2026 and the expiry of royalty income on diabetes products at the end of 2025. After adjusting for specified items, the $0.22 decrease in non-GAAP EPS was primarily due to the expiry of royalty income on diabetes products at the end of 2025.
Our non-GAAP financial measures, including non-GAAP earnings and related EPS information, are adjusted to exclude specified items that represent certain costs, expenses, gains and losses and other items impacting the comparability of financial results. For further information and reconciliations relating to our non-GAAP financial measures refer to "—Non-GAAP Financial Measures."
25
Economic and Market Factors
Governmental Actions
Ongoing regulatory focus on prescription drugs has increased pressures across our portfolio. These pressures have resulted in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse, which have negatively impacted, and may continue to negatively impact our results of operations (including intangible asset impairment charges), operating cash flow, liquidity and financial flexibility. Under the IRA, the HHS announced the "maximum fair price" for a 30-day equivalent supply of Eliquis, which applies to the U.S. Medicare channel effective January 1, 2026 and the "maximum fair price" for a 30-day supply of Pomalyst, which applies to the U.S. Medicare channel effective January 1, 2027. Additionally, in January 2026, the HHS selected Orencia as a medicine subject to "negotiation" for government-set prices beginning in 2028. It is possible that more of our products could be selected in future years based upon the selection criteria currently utilized by the HHS or potentially expanded future criteria, or that the "maximum fair price" for our previously selected products could be renegotiated, each of which could, among other things, accelerate revenue erosion prior to expiry of intellectual property protections. We continue to evaluate the impact of the IRA on our results of operations, and it is possible that these changes may result in a material impact on our business and results of operations.
In December 2025, we announced the U.S. Government Agreement pursuant to which we agreed to, among other things: (i) provide Eliquis for free to the Medicaid program effective January 1, 2026; (ii) donate more than seven tons of Eliquis API to fill the U.S. Strategic Active Ingredient Reserve; (iii) enable direct-to-patient access to Sotyktu, Zeposia, Reyataz, Baraclude and Orencia for cash-paying patients at discounts approximately 80% off current list prices; (iv) adopt a more balanced pricing approach for new launches across developed nations; and (v) continue to expand domestic production. This agreement, and any potential future agreements with government entities, by us or our competitors, could result in reduced prices and reimbursement for certain of our or competing products and may impact our cash flows and results of operations.
In accordance with the U.S. Government Agreement, BMS will receive certain U.S. tariff relief until January 2029, including for recently imposed tariffs relating to patented pharmaceuticals and associated pharmaceutical ingredients pursuant to the Presidential Proclamation dated April 2, 2026, and will not be subject to future pricing mandates in the U.S. while the agreement remains in effect. However, such exemptions may be terminated or may not be extended. In addition, we remain subject to any current or future pricing mandates implemented outside of the U.S. It is possible that such regulations may result in a material impact on our business and results of operations.
See risk factors on governmental action items included under “Part I—Item 1A. Risk Factors—Product, Industry and Operational Risks—Increased pricing pressure and other restrictions in the U.S. and abroad continue to negatively affect our revenues and profit margins”, “—We could lose market exclusivity of a product earlier than expected”, “—We could experience difficulties, delays and disruptions in our supply chain as well as in the manufacturing, distribution and sale of our products”, “—Changes to tax regulations could negatively impact our earnings” and "—Adverse changes in U.S. and global economic and political conditions could adversely affect our operations and profitability" in our 2025 Form 10-K.
Significant Product and Pipeline Approvals
The following is a summary of the significant approvals received in 2026 as of April 30, 2026:
| Product | Date | Approval | ||||||
Breyanzi | April 2026 | Japan's Ministry of Health Labour and Welfare approval of Breyanzi for the treatment of both relapsed or refractory MCL and relapsed or refractory MZL. | ||||||
Opdivo | March 2026 | Announced FDA approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV cHL. Announced EC approval of Opdivo in combination with brentuximab vedotin, for the treatment of children 5 years of age and older, adolescents, and adults up to 30 years of age with relapsed or refractory cHL after one prior line of therapy. | ||||||
| Sotyktu | March 2026 | Announced FDA approval of Sotyktu, for the treatment of adults with active PsA. | ||||||
Refer to "—Product and Pipeline Developments" for a listing of other developments in our marketed products and late-stage pipeline since the start of the first quarter of 2026.
26
Acquisitions, Divestitures, Licensing and Other Arrangements
Refer to "Item 1. Financial Statements—Note 3. Alliances" and "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements" for information on significant acquisitions, divestitures, licensing and other arrangements.
RESULTS OF OPERATIONS
Regional Revenues
The composition of the changes in revenues was as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | % Change | Foreign Exchange(b) | |||||||||||||||||||||||||||||||||||||||||||
| United States | $ | 7,788 | $ | 7,873 | (1) | % | — | % | |||||||||||||||||||||||||||||||||||||||
International | 3,444 | 3,110 | 11 | % | 8 | % | |||||||||||||||||||||||||||||||||||||||||
Other(a) | 257 | 218 | 18 | % | (7) | % | |||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | 11,489 | $ | 11,201 | 3 | % | 2 | % | |||||||||||||||||||||||||||||||||||||||
(a) Includes royalties and alliance-related revenues for products not sold by our regional commercial organizations, including royalties received from Merck on Winrevair*.
(b) Foreign exchange impacts were derived by applying the prior period average currency rates to the current period revenues.
United States
•U.S. revenues decreased 1% during the first quarter of 2026, reflecting higher demand across the Growth Portfolio and for Eliquis, offset by the impact of generic erosion within the remainder of the Legacy Portfolio. Additionally, revenues were impacted by lower average net selling prices for the Legacy Portfolio. Average U.S. net selling prices decreased 1% compared to the corresponding period a year ago.
International
•International revenues increased 11% during the first quarter of 2026, primarily due to higher demand across the Growth Portfolio and for Eliquis, partially offset by generic erosion within the remainder of the Legacy Portfolio. Excluding the impacts of foreign exchange, international revenues increased 3% during the first quarter of 2026.
No single country outside the U.S. contributed more than 10% of total revenues during the three months ended March 31, 2026 and 2025. Our business is typically not seasonal; however, in the first quarter we typically see an unwinding of sales channel inventory build-up from the fourth quarter of the prior year.
27
GTN Adjustments
The reconciliation of gross product sales to net product sales by each significant category of GTN adjustments was as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | % Change | ||||||||||||||||||||||||||||||||
| Gross product sales | $ | 16,926 | $ | 19,874 | (15) | % | |||||||||||||||||||||||||||||
| GTN adjustments | |||||||||||||||||||||||||||||||||||
| Charge-backs and cash discounts | (2,467) | (2,958) | (17) | % | |||||||||||||||||||||||||||||||
| Medicaid and Medicare rebates | (1,875) | (3,840) | (51) | % | |||||||||||||||||||||||||||||||
| Other rebates, returns, discounts and adjustments | (1,416) | (2,190) | (35) | % | |||||||||||||||||||||||||||||||
| Total GTN adjustments | (5,758) | (8,988) | (36) | % | |||||||||||||||||||||||||||||||
| Net product sales | $ | 11,168 | $ | 10,886 | 3 | % | |||||||||||||||||||||||||||||
| GTN adjustments percentage | 34 | % | 45 | % | (11) | % | |||||||||||||||||||||||||||||
| U.S. | 38 | % | 51 | % | (13) | % | |||||||||||||||||||||||||||||
| Non-U.S. | 21 | % | 21 | % | — | % | |||||||||||||||||||||||||||||
Reductions/(increases) to provisions for product sales made in prior periods resulting from changes in estimates were $(21) million and $289 million for the three months ended March 31, 2026 and 2025, respectively. The reduction to provision recognized for the three months ended March 31, 2025 primarily related to lower than expected Medicaid utilization. The changes in gross product sales and GTN adjustments were primarily due to a list price reduction for Eliquis in the U.S. in 2026.
GTN adjustments are primarily a function of product sales volume, regional and payer channel mix, contractual or legislative discounts and rebates.
28
Product Revenues
| Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | % Change | ||||||||||||||||||||||||||||||||
Growth Portfolio | |||||||||||||||||||||||||||||||||||
| Opdivo | $ | 2,146 | $ | 2,265 | (5) | % | |||||||||||||||||||||||||||||
| U.S. | 1,159 | 1,332 | (13) | % | |||||||||||||||||||||||||||||||
International & Other | 988 | 933 | 6 | % | |||||||||||||||||||||||||||||||
Opdivo Qvantig | 163 | 9 | >200% | ||||||||||||||||||||||||||||||||
| U.S. | 131 | 8 | >200% | ||||||||||||||||||||||||||||||||
International & Other | 32 | — | >200% | ||||||||||||||||||||||||||||||||
| Orencia | 818 | 770 | 6 | % | |||||||||||||||||||||||||||||||
| U.S. | 590 | 555 | 6 | % | |||||||||||||||||||||||||||||||
International & Other | 228 | 215 | 6 | % | |||||||||||||||||||||||||||||||
| Yervoy | 651 | 624 | 4 | % | |||||||||||||||||||||||||||||||
| U.S. | 367 | 394 | (7) | % | |||||||||||||||||||||||||||||||
International & Other | 284 | 230 | 24 | % | |||||||||||||||||||||||||||||||
| Reblozyl | 555 | 478 | 16 | % | |||||||||||||||||||||||||||||||
| U.S. | 440 | 390 | 13 | % | |||||||||||||||||||||||||||||||
International & Other | 116 | 89 | 30 | % | |||||||||||||||||||||||||||||||
| Breyanzi | 411 | 263 | 56 | % | |||||||||||||||||||||||||||||||
| U.S. | 292 | 204 | 43 | % | |||||||||||||||||||||||||||||||
International & Other | 120 | 60 | 101 | % | |||||||||||||||||||||||||||||||
| Opdualag | 295 | 252 | 17 | % | |||||||||||||||||||||||||||||||
| U.S. | 246 | 228 | 8 | % | |||||||||||||||||||||||||||||||
International & Other | 49 | 25 | 98 | % | |||||||||||||||||||||||||||||||
| Camzyos | 314 | 159 | 97 | % | |||||||||||||||||||||||||||||||
| U.S. | 229 | 126 | 82 | % | |||||||||||||||||||||||||||||||
International & Other | 85 | 33 | 155 | % | |||||||||||||||||||||||||||||||
| Zeposia | 118 | 107 | 11 | % | |||||||||||||||||||||||||||||||
| U.S. | 69 | 61 | 14 | % | |||||||||||||||||||||||||||||||
International & Other | 49 | 46 | 7 | % | |||||||||||||||||||||||||||||||
| Sotyktu | 69 | 55 | 24 | % | |||||||||||||||||||||||||||||||
| U.S. | 35 | 32 | 10 | % | |||||||||||||||||||||||||||||||
International & Other | 33 | 23 | 43 | % | |||||||||||||||||||||||||||||||
| Krazati | 50 | 48 | 4 | % | |||||||||||||||||||||||||||||||
| U.S. | 46 | 44 | 4 | % | |||||||||||||||||||||||||||||||
International & Other | 3 | 4 | (6) | % | |||||||||||||||||||||||||||||||
Cobenfy | 56 | 27 | 107 | % | |||||||||||||||||||||||||||||||
| U.S. | 56 | 27 | 107 | % | |||||||||||||||||||||||||||||||
International & Other | — | — | N/A | ||||||||||||||||||||||||||||||||
Other Growth Products(a) | 581 | 507 | 15 | % | |||||||||||||||||||||||||||||||
| U.S. | 212 | 233 | (9) | % | |||||||||||||||||||||||||||||||
International & Other | 369 | 274 | 35 | % | |||||||||||||||||||||||||||||||
| Total Growth Portfolio | $ | 6,227 | $ | 5,563 | 12 | % | |||||||||||||||||||||||||||||
| U.S. | 3,872 | 3,633 | 7 | % | |||||||||||||||||||||||||||||||
International & Other | 2,355 | 1,930 | 22 | % | |||||||||||||||||||||||||||||||
29
Legacy Portfolio | |||||||||||||||||||||||||||||||||||
| Eliquis | $ | 4,137 | $ | 3,565 | 16 | % | |||||||||||||||||||||||||||||
| U.S. | 3,077 | 2,646 | 16 | % | |||||||||||||||||||||||||||||||
International & Other | 1,059 | 919 | 15 | % | |||||||||||||||||||||||||||||||
| Revlimid | 349 | 936 | (63) | % | |||||||||||||||||||||||||||||||
| U.S. | 278 | 809 | (66) | % | |||||||||||||||||||||||||||||||
International & Other | 71 | 127 | (44) | % | |||||||||||||||||||||||||||||||
| Pomalyst/Imnovid | 513 | 658 | (22) | % | |||||||||||||||||||||||||||||||
| U.S. | 439 | 537 | (18) | % | |||||||||||||||||||||||||||||||
International & Other | 74 | 122 | (39) | % | |||||||||||||||||||||||||||||||
| Sprycel | 73 | 175 | (58) | % | |||||||||||||||||||||||||||||||
| U.S. | 36 | 126 | (71) | % | |||||||||||||||||||||||||||||||
International & Other | 37 | 49 | (25) | % | |||||||||||||||||||||||||||||||
| Abraxane | 50 | 105 | (53) | % | |||||||||||||||||||||||||||||||
| U.S. | 12 | 40 | (71) | % | |||||||||||||||||||||||||||||||
International & Other | 38 | 65 | (42) | % | |||||||||||||||||||||||||||||||
Other Legacy Products(b) | 156 | 199 | (21) | % | |||||||||||||||||||||||||||||||
| U.S. | 74 | 82 | (10) | % | |||||||||||||||||||||||||||||||
International & Other | 82 | 116 | (30) | % | |||||||||||||||||||||||||||||||
Total Legacy Portfolio | $ | 5,277 | $ | 5,638 | (6) | % | |||||||||||||||||||||||||||||
| U.S. | 3,916 | 4,240 | (8) | % | |||||||||||||||||||||||||||||||
International & Other | 1,361 | 1,398 | (3) | % | |||||||||||||||||||||||||||||||
Other revenue(c) | $ | (15) | $ | — | N/A | ||||||||||||||||||||||||||||||
International & Other | (15) | — | N/A | ||||||||||||||||||||||||||||||||
Total Revenues | $ | 11,489 | $ | 11,201 | 3 | % | |||||||||||||||||||||||||||||
| U.S. | 7,788 | 7,873 | (1) | % | |||||||||||||||||||||||||||||||
International & Other | 3,701 | 3,328 | 11 | % | |||||||||||||||||||||||||||||||
(a) Includes Abecma, Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues, including royalties received from Merck on Winrevair*.
(b) Includes other mature brands.
(c) Includes revenue hedging activities in 2026.
30
Growth Portfolio
•Opdivo revenues decreased 5% during the first quarter of 2026, primarily due to changes in sales channel inventory and timing of customer orders in the U.S., partially offset by foreign exchange impacts of 3%. Excluding foreign exchange impacts, revenues decreased 8%.
•Opdivo Qvantig revenues increased more than 200% during the first quarter of 2026, primarily due to higher demand as a result of the product's launch in 2025.
•Orencia revenues increased 6% during the first quarter of 2026, primarily due to higher demand in the U.S. and foreign exchange impacts of 2%. Excluding foreign exchange impacts, revenues increased 5%. Formulation and additional patents expire in 2026 and beyond. In April 2026, BMS entered into agreements with Dr. Reddy's Laboratories that allow for (i) an Orencia biosimilar for intravenous administration to be marketed in the U.S. upon approval and (ii) an Orencia biosimilar for subcutaneous administration to be marketed in the U.S. as early as February 2028. BMS is not aware of an Orencia biosimilar currently on the market in the U.S., EU or Japan.
•Yervoy revenues increased 4% during the first quarter of 2026, primarily due to higher demand across international markets and foreign exchange impacts of 3%. Excluding foreign exchange impacts, revenues increased 2%. BMS is not aware of a Yervoy biosimilar on the market in the U.S., EU or Japan.
•Reblozyl revenues increased 16% during the first quarter of 2026, primarily due to higher demand and foreign exchange impacts of 1%. Excluding foreign exchange impacts, revenues increased 15%.
•Breyanzi revenues increased 56% during the first quarter of 2026, primarily due to higher demand and foreign exchange impacts of 3%. Excluding foreign exchange impacts, revenues increased 53%.
•Opdualag revenues increased 17% during the first quarter of 2026, primarily due to higher demand and foreign exchange impacts of 2%. Excluding foreign exchange impacts, revenues increased 15%.
•Camzyos revenues increased 97% during the first quarter of 2026, primarily due to higher demand and foreign exchange impacts of 4%. Excluding foreign exchange impacts, revenues increased 94%.
•Zeposia revenues increased 11% during the first quarter of 2026, primarily due to higher demand in the U.S. and foreign exchange impacts of 4%. Excluding foreign exchange impacts, revenues increased 7%.
•Sotyktu revenues increased 24% during the first quarter of 2026, primarily due to higher demand across international markets and foreign exchange impacts of 4%. Excluding foreign exchange impacts, revenues increased 20%.
•Krazati revenues increased 4% during the first quarter of 2026, primarily due to higher demand in the U.S. and foreign exchange impacts of 1%. Excluding foreign exchange impacts, revenues increased 3%.
•Cobenfy revenues increased 107% during the first quarter of 2026, primarily due to higher demand in the U.S.
Legacy Portfolio
•Eliquis revenues increased 16% during the first quarter of 2026, primarily due to higher demand in the U.S. and foreign exchange impacts of 3%. Excluding foreign exchange impacts, revenues increased 13%. Following the May 2021 expiration of regulatory exclusivity for Eliquis in Europe, generic manufacturers have sought to challenge our Eliquis patents and related SPCs and have begun marketing generic versions of Eliquis in certain countries prior to the expiry of our patents and related SPCs, which has led to the filing of infringement and invalidity actions involving our Eliquis patents and related SPCs being filed in various countries in Europe. In the EU, the apixaban composition of matter patents and related SPCs expire in November 2026. Additionally, in November 2025, BMS and Pfizer initiated a patent infringement action against an applicant seeking approval to market apixaban products in the U.S. We believe in the innovative science behind Eliquis and the strength of our intellectual property, which we will defend against infringement. Refer to "Item 1. Financial Statements—Note 18. Legal Proceedings and Contingencies—Intellectual Property" for further information.
31
•Revlimid revenues decreased 63% during the first quarter of 2026, primarily due to lower demand in the U.S. as a result of generic erosion. In the U.S., certain third parties have been granted volume-limited licenses to sell generic lenalidomide. Pursuant to these licenses, several generics have entered or are expected to enter the U.S. market with volume-limited quantities of generic lenalidomide. As of January 31, 2026, these licenses are no longer volume-limited. In the EU and Japan, generic lenalidomide products have entered the market.
•Pomalyst/Imnovid revenues decreased 22% during the first quarter of 2026, primarily due to lower demand as a result of generic erosion. In the U.S. (March 2026) and EU, generics have entered the market.
•Sprycel revenues decreased 58% during the first quarter of 2026, primarily due to lower demand as a result of generic erosion. Excluding foreign exchange impacts, revenues decreased 59%. In the U.S., EU and Japan, generics have entered the market.
•Abraxane revenues decreased 53% during the first quarter of 2026, primarily due to lower demand as a result of generic erosion, partially offset by foreign exchange impacts of 1%. Excluding foreign exchange impacts, revenues decreased 54%.
Estimated End-User Demand
Pursuant to the SEC Consent Order described under "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations— SEC Consent Order" in our 2025 Form 10-K, we monitor inventory levels on hand in the U.S. wholesaler distribution channel and outside of the U.S. in the direct customer distribution channel. We disclose products with levels of inventory in excess of one month on hand or expected demand, subject to certain limited exceptions. There were none as of March 31, 2026, for our U.S. distribution channels, and as of December 31, 2025, for our non-U.S. distribution channels.
In the U.S., we generally determine our months on hand estimates using inventory levels of product on hand and the amount of out-movement provided by our three largest wholesalers, which accounted for approximately 90% of total gross sales of U.S. products during the three months ended March 31, 2026. Factors that may influence our estimates include generic erosion, seasonality of products, wholesaler purchases in light of increases in wholesaler list prices, new product launches, new warehouse openings by wholesalers and new customer stockings by wholesalers. In addition, these estimates are calculated using third-party data, which may be impacted by their recordkeeping processes.
Camzyos is only available through a restricted program called the Camzyos REMS Program. Product distribution is limited to REMS certified pharmacies, and enrolled pharmacies must only dispense to patients who are authorized to receive Camzyos. Revlimid and Pomalyst are distributed in the U.S. primarily through contracted pharmacies under the Lenalidomide REMS (Revlimid) and Pomalyst REMS programs, respectively. These are proprietary risk-management distribution programs tailored specifically to provide for the safe and appropriate distribution and use of Revlimid and Pomalyst. Internationally, Revlimid and Imnovid are distributed under mandatory risk-management distribution programs tailored to meet local authorities' specifications to provide for the products' safe and appropriate distribution and use. These programs may vary by country and, depending upon the country and the design of the risk-management program, the product may be sold through hospitals or retail pharmacies.
Our non-U.S. businesses have significantly more direct customers. Information on available direct customer product level inventory and corresponding out-movement information and the reliability of third-party demand information varies widely. We limit our direct customer sales channel inventory reporting to where we can influence demand. When this information does not exist or is otherwise not available, we have developed a variety of methodologies to estimate such data, including using historical sales made to direct customers and third-party market research data related to prescription trends and end-user demand. Given the difficulties inherent in estimating third-party demand information, we evaluate our methodologies to estimate direct customer product level inventory and to calculate months on hand on an ongoing basis and make changes as necessary. Factors that may affect our estimates include generic competition, seasonality of products, price increases, new product launches, new warehouse openings by direct customers, new customer stockings by direct customers and expected direct customer purchases for governmental bidding situations. As such, all of the information required to estimate months on hand in the direct customer distribution channel for non-U.S. business during the three months ended March 31, 2026 is not available prior to the filing of this Quarterly Report on Form 10-Q. We will disclose any product with levels of inventory in excess of one month on hand or expected demand for the current quarter, subject to certain limited exceptions, in our next quarterly report on Form 10-Q.
32
Expenses
| Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | % Change | ||||||||||||||||||||||||||||||||
Cost of products sold(a) | $ | 3,421 | $ | 3,033 | 13 | % | |||||||||||||||||||||||||||||
Selling, general and administrative | 1,617 | 1,584 | 2 | % | |||||||||||||||||||||||||||||||
| Research and development | 2,649 | 2,257 | 17 | % | |||||||||||||||||||||||||||||||
| Acquired IPRD | 94 | 188 | (50) | % | |||||||||||||||||||||||||||||||
| Amortization of acquired intangible assets | 437 | 830 | (47) | % | |||||||||||||||||||||||||||||||
| Other (income)/expense, net | 32 | 339 | (90) | % | |||||||||||||||||||||||||||||||
| Total Expenses | $ | 8,250 | $ | 8,230 | — | % | |||||||||||||||||||||||||||||
(a) Excludes amortization of acquired intangible assets.
Cost of Products Sold
Cost of products sold increased by $388 million in the first quarter of 2026, primarily due to higher alliance profit sharing and product mix.
Selling, General and Administrative
Selling, general and administrative expense increased by $32 million in the first quarter of 2026, primarily due to higher investments in new product launches, partially offset by cost savings from the Company's ongoing strategic productivity initiative.
Research and Development
Research and development expense increased by $393 million in the first quarter of 2026, primarily due to IPRD impairment charges of $410 million, partially offset by cost savings from the Company's ongoing strategic productivity initiative.
Acquired IPRD
Acquired IPRD charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights were as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
BioArctic upfront fee | $ | — | $ | 100 | |||||||||||||||||||
| Evotec designation and opt-in license fees | 10 | 83 | |||||||||||||||||||||
| Other | 84 | 5 | |||||||||||||||||||||
| Acquired IPRD | $ | 94 | $ | 188 | |||||||||||||||||||
Amortization of Acquired Intangible Assets
Amortization of acquired intangible assets decreased by $393 million in the first quarter of 2026, primarily due to the lower amortization expense related to Pomalyst. The Pomalyst acquired marketed product right was fully amortized in the fourth quarter of 2025.
33
Other (Income)/Expense, Net
Other (income)/expense, net changed by $306 million in the first quarter of 2026 as discussed below.
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
| Interest expense | $ | 411 | $ | 494 | |||||||||||||||||||
| Royalty income - divestitures | — | (272) | |||||||||||||||||||||
Royalty and licensing income | (195) | (259) | |||||||||||||||||||||
| Investment income | (104) | (138) | |||||||||||||||||||||
| Provision for restructuring | 5 | 133 | |||||||||||||||||||||
| Litigation and other settlements | 4 | 257 | |||||||||||||||||||||
Equity investment (gains)/losses | (134) | 78 | |||||||||||||||||||||
Integration expenses | 19 | 41 | |||||||||||||||||||||
| Other | 27 | 4 | |||||||||||||||||||||
Other (income)/expense, net | $ | 32 | $ | 339 | |||||||||||||||||||
•As part of our diabetes termination agreement with AstraZeneca, we received royalty payments based on net sales, which terminated as of December 31, 2025.
•Litigation and other settlements includes amounts related to pricing, sales and promotional practices disputes in the first quarter of 2025.
•Gains on equity investments during the first quarter of 2026 are primarily driven by upward adjustments in equity investments without RDFV. Refer to “Item 1. Financial Statements—Note 9. Financial Instruments and Fair Value Measurements” for more information.
Income Taxes
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
| Earnings/(Loss) before income taxes | $ | 3,240 | $ | 2,971 | |||||||||||||||||||
Income tax provision | 561 | 509 | |||||||||||||||||||||
| Effective tax rate | 17.3 | % | 17.1 | % | |||||||||||||||||||
| Impact of specified items | 0.9 | % | (2.1) | % | |||||||||||||||||||
| Effective tax rate excluding specified items | 18.3 | % | 15.1 | % | |||||||||||||||||||
Provision for income taxes in interim periods is determined based on the estimated annual effective tax rates and the tax impact of discrete items that are reflected immediately. The increase in the effective tax rate was primarily driven by jurisdictional earnings mix, partially offset by the impact of certain discrete adjustments. Excluding the impact of specified items, the increase in the effective tax rate was primarily driven by jurisdictional earnings mix.
34
Non-GAAP Financial Measures
Our non-GAAP financial measures, such as non-GAAP earnings and related EPS information, are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. These items are excluded from non-GAAP earnings and related EPS information because the Company believes they neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including (i) amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, (ii) unwinding of inventory purchase price adjustments, (iii) integration expenses, (iv) restructuring costs, (v) accelerated depreciation and impairment of property, plant and equipment and intangible assets, (vi) divestiture gains or losses, (vii) pension, legal and other contractual settlement charges, (viii) equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnerships and other investments), and (ix) amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates, as well as certain other significant tax items. We also provide worldwide and international revenues for our priority products excluding the impact of foreign exchange. We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are included in Exhibit 99.1 to our Form 8-K filed on April 30, 2026 and are incorporated herein by reference.
Non-GAAP information is intended to portray the results of our baseline performance, supplement or enhance management's, analysts' and investors’ overall understanding of our underlying financial performance and facilitate comparisons among current, past and future periods. This information is not intended to be considered in isolation or as a substitute for the related financial measures prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.
35
Specified items were as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||||||||||||||
| Inventory purchase price accounting adjustments | $ | 13 | $ | 13 | |||||||||||||||||||
| Site exit and other costs | — | 2 | |||||||||||||||||||||
| Cost of products sold | 13 | 14 | |||||||||||||||||||||
| Site exit and other costs | — | 1 | |||||||||||||||||||||
Selling, general and administrative | — | 1 | |||||||||||||||||||||
| IPRD impairments | 410 | — | |||||||||||||||||||||
| Site exit and other costs | 1 | 21 | |||||||||||||||||||||
| Research and development | 411 | 21 | |||||||||||||||||||||
| Amortization of acquired intangible assets | 437 | 830 | |||||||||||||||||||||
Interest expense | (9) | (12) | |||||||||||||||||||||
| Provision for restructuring | 5 | 133 | |||||||||||||||||||||
| Litigation and other settlements | — | 246 | |||||||||||||||||||||
| Equity investment (gains)/losses | (134) | 77 | |||||||||||||||||||||
| Integration expenses | 19 | 41 | |||||||||||||||||||||
| Other | (22) | 3 | |||||||||||||||||||||
| Other (income)/expense, net | (140) | 489 | |||||||||||||||||||||
Increase to earnings/(loss) before income taxes | 721 | 1,356 | |||||||||||||||||||||
| Income taxes on items above | (161) | (143) | |||||||||||||||||||||
Increase to net earnings/(loss) attributable to BMS | $ | 560 | $ | 1,212 | |||||||||||||||||||
The reconciliations from GAAP to Non-GAAP were as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||
| Dollars in millions, except per share data | 2026 | 2025 | |||||||||||||||||||||
| Net earnings/(loss) attributable to BMS | |||||||||||||||||||||||
| GAAP | $ | 2,677 | $ | 2,456 | |||||||||||||||||||
| Specified items | 560 | 1,212 | |||||||||||||||||||||
| Non-GAAP | $ | 3,237 | $ | 3,668 | |||||||||||||||||||
| Weighted-average common shares outstanding – diluted | 2,047 | 2,040 | |||||||||||||||||||||
| Diluted earnings/(loss) per share attributable to BMS | |||||||||||||||||||||||
| GAAP | $ | 1.31 | $ | 1.20 | |||||||||||||||||||
| Specified items | 0.27 | 0.59 | |||||||||||||||||||||
| Non-GAAP | $ | 1.58 | $ | 1.80 | |||||||||||||||||||
36
FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES
Our net debt position was as follows:
| Dollars in Millions | March 31, 2026 | December 31, 2025 | |||||||||
| Cash and cash equivalents | $ | 9,574 | $ | 10,209 | |||||||
| Marketable debt securities – current | 912 | 464 | |||||||||
| Marketable debt securities – non-current | 366 | 396 | |||||||||
| Total cash, cash equivalents and marketable debt securities | 10,853 | 11,069 | |||||||||
| Short-term debt obligations | (2,308) | (2,261) | |||||||||
| Long-term debt | (42,152) | (42,850) | |||||||||
| Net debt position | $ | (33,607) | $ | (34,043) | |||||||
We believe that our existing cash, cash equivalents and marketable debt securities together with our ability to generate cash from operations and our access to short-term and long-term borrowings are sufficient to satisfy our existing and anticipated cash needs for at least the next few years, including dividends, capital expenditures, milestone payments, working capital, income taxes, restructuring initiatives, business development, business combinations, asset acquisitions, repurchase of common stock, debt maturities, as well as any debt repurchases through redemptions or tender offers. During the three months ended March 31, 2026, our net debt position decreased by $436 million primarily driven by cash provided by operations of $1.1 billion and proceeds from the sale of equity investment securities, partially offset by dividend payments of $1.3 billion.
During the three months ended March 31, 2026, $500 million of floating rate notes matured and were repaid.
Under our commercial paper program, we may issue a maximum of $5.0 billion of unsecured notes with maturities of not more than 365 days from the date of issuance.
As of March 31, 2026 and December 31, 2025, we had a five-year $5.0 billion revolving credit facility, which is extendable annually by one year with the consent of the lenders. In January 2026, we extended the termination date of the credit facility from January 2030 to January 2031. No borrowings were outstanding under the revolving credit facility as of March 31, 2026 and December 31, 2025.
Dividend payments were $1.3 billion during the three months ended March 31, 2026. The decision to authorize dividends is made on a quarterly basis by our Board of Directors.
During the three months ended March 31, 2026 and 2025, income tax payments were $239 million and $235 million.
Cash Flows
The following is a discussion of cash flow activities:
| Three Months Ended March 31, | |||||||||||
| Dollars in millions | 2026 | 2025 | |||||||||
| Cash flow provided by/(used in): | |||||||||||
| Operating activities | $ | 1,104 | $ | 1,954 | |||||||
| Investing activities | (131) | (499) | |||||||||
| Financing activities | (1,560) | (993) | |||||||||
Operating Activities
The $850 million decrease in cash provided by operating activities compared to 2025 was driven by lower net customer receipts, primarily due to a list price reduction for Eliquis, and higher litigation-related disbursements, partially offset by lower expenses due to the ongoing strategic productivity initiative.
Investing Activities
Cash used in investing activities during 2026 was primarily driven by net purchases of marketable debt securities of $422 million, partially offset by proceeds from the sale of equity investment securities of $391 million.
37
Financing Activities
Cash used in financing activities during 2026 was primarily driven by dividend payments of $1.3 billion and the repayment of $500 million of floating rate notes.
Product and Pipeline Developments
Our R&D programs are managed on a portfolio basis from early discovery through late-stage development and include a balance of early-stage and late-stage programs to support future growth. Our late-stage R&D programs in Phase III development include both investigational compounds for initial indications and additional indications or formulations for marketed products. The following are the developments in our marketed products and our late-stage pipeline since the start of the first quarter of 2026 as of April 30, 2026:
| Product | Indication | Date | Developments | ||||||||
Breyanzi | MCL & MZL | April 2026 | Japan's Ministry of Health Labour and Welfare approval of Breyanzi for the treatment of both relapsed or refractory MCL and relapsed or refractory MZL. This approval is based on Cohort 4 of the Phase II TRANSCEND FL study and the MCL cohort of the Phase I TRANSCEND NHL study. | ||||||||
Camzyos | oHCM | March 2026 | Announced positive data from the Phase III SCOUT-HCM trial of Camzyos, the first study of a cardiac myosin inhibitor (CMI) in adolescents (ages 12 years to <18 years) with symptomatic oHCM. The trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant reduction from baseline in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 versus placebo. Additionally, Camzyos showed meaningful improvement over placebo in multiple secondary endpoints at 28 weeks, and similar safety findings were observed in the Camzyos and placebo groups. | ||||||||
Cobenfy | Schizophrenia | March 2026 | Announced data from Phase IV clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy when switching adult outpatients with schizophrenia from an oral atypical antipsychotic to Cobenfy monotherapy. Through 8 weeks, patients remained stable with mean Positive and Negative Syndrome Scale (PANSS) total scores remaining below baseline, and no new safety signals were observed, regardless of cross-titration duration. These findings provide important evidence to help inform treatment switch strategies in clinical practice. | ||||||||
| iberdomide | RRMM | February 2026 | The FDA has accepted an NDA for iberdomide combined with standard treatment (daratumumab + dexamethasone - IberDd) in patients with RRMM. The FDA has granted a PDUFA date of August 17, 2026 for this indication. The filing was based on results from a planned analysis of MRD negativity rates in the Phase III EXCALIBER-RRMM study evaluating iberdomide as a treatment for RRMM patients. The EXCALIBER-RRMM trial is ongoing and patients continue to be evaluated for PFS. | ||||||||
iza-bren | TNBC | February 2026 | Announced with SystImmune that SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd., reported positive interim topline results from BL-B01D1-307, a Phase III study conducted in China evaluating iza-bren in patients with unresectable locally advanced or metastatic TNBC whose disease progressed following prior taxane therapy. In the pre-specified interim analysis, topline results showed that iza-bren demonstrated statistically significant and clinically meaningful improvement in both PFS and overall survival (OS) compared to chemotherapy of physician’s choice, meeting both dual primary endpoints. | ||||||||
| mezigdomide | RRMM | March 2026 | Announced positive interim Phase III results from the SUCCESSOR-2 study. In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in PFS versus carfilzomib and dexamethasone alone (Kd) in patients with RRMM. Safety findings were consistent with the known profile of mezigdomide and the combination regimen. Patients will continue to be followed for survival and safety. | ||||||||
38
obexelimab | IgG4-RD | January 2026 | Our partner, Zenas BioPharma, Inc., announced positive results from the Phase III INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD). Obexelimab met the primary endpoint, demonstrating a highly statistically significant and clinically meaningful 56% reduction in the risk of IgG4-RD flare compared to placebo during the 52-week randomized placebo-controlled period. Obexelimab also met and demonstrated highly statistically significant activity compared to placebo on all four key secondary endpoints, which were reduction in investigator assessed IgG4-RD flare, the number of flares requiring rescue therapy, the proportion of patients achieving complete remission and the cumulative use of IgG4-RD rescue therapy. Rates of infections, including Grade 3, were lower in the obexelimab arm compared to placebo, and the incidence of injection site reactions was similar across both study arms. | ||||||||
Opdivo | cHL | March 2026 | Announced FDA approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV cHL. The approval is based on results from the Phase III SWOG 1826 study, which demonstrated a statistically significant improvement in the primary endpoint of PFS for patients who received Opdivo in combination with AVD. Announced EC approval of Opdivo in combination with brentuximab vedotin, for the treatment of children 5 years of age and older, adolescents, and adults up to 30 years of age with relapsed or refractory cHL after one prior line of therapy. The approval is based on results from the Phase II CheckMate -744 study. | ||||||||
Reblozyl | Anemia | February 2026 | Announced positive topline Phase II results from the registrational study NCT05664737, evaluating Reblozyl versus placebo for anemia in adults with Alpha-Thalassemia. The NTD and TD cohorts of the study met their respective primary endpoints, with Reblozyl demonstrating a statistically significant and clinically meaningful increase in hemoglobin levels in NTD patients with Alpha‑Thalassemia, and a statistically significant and clinically meaningful decrease in red blood cell (RBC) transfusion burden in TD patients with Alpha‑Thalassemia. The study also met all key secondary endpoints. | ||||||||
| Sotyktu | PsA | March 2026 | Announced FDA approval of Sotyktu, for the treatment of adults with active PsA. This approval is based on the positive results from the pivotal Phase III POETYK PsA-1 and POETYK PsA-2 trials. | ||||||||
Critical Accounting Policies
The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Our critical accounting policies are those that significantly impact our financial condition and results of operations and require the most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of this uncertainty, actual results may vary from these estimates. For a discussion of our critical accounting policies, refer to "Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations" in our 2025 Form 10-K. There have been no material changes to our critical accounting policies during the three months ended March 31, 2026. For information regarding the impact of recently adopted accounting standards, refer to "Item 1. Financial Statements—Note 1. Basis of Presentation and Recently Issued Accounting Standards."
39
Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (including documents incorporated by reference) and other written and oral statements we make from time to time contain certain “forward-looking” statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. You can identify these forward-looking statements by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on our current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These statements are likely to relate to, among other things, our goals, plans and objectives regarding our financial position, results of operations, cash flows, market position, product development, product approvals, sales efforts, expenses, performance or results of current and anticipated products, our business development strategy and in relation to our ability to realize the projected benefits of our acquisitions, alliances and other business development activities, the impact of any pandemic or epidemic on our operations and the development and commercialization of our products, laws, agreements and regulations to lower drug prices, government actions relating to the imposition of new tariffs, market actions taken by private and government payers to manage drug utilization and contain costs, the expiration of patents or data protection on certain products, including assumptions about our ability to retain marketing exclusivity of certain products, and the outcome of contingencies such as legal proceedings and financial results. No forward-looking statement can be guaranteed. This Quarterly Report on Form 10-Q, our 2025 Form 10-K, particularly under the section "Item 1A. Risk Factors," and our other filings with the SEC, include additional information on the factors that we believe could cause actual results to differ materially from any forward-looking statement.
Although we believe that we have been prudent in our plans and assumptions, no assurance can be given that any goal or plan set forth in forward-looking statements can be achieved and readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. Additional risks that we may currently deem immaterial or that are not presently known to us could also cause the forward-looking events discussed in this Quarterly Report on Form 10-Q not to occur. Except as otherwise required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise after the date of this Quarterly Report on Form 10-Q.
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of our market risk, refer to "Item 7A. Quantitative and Qualitative Disclosures about Market Risk" in our 2025 Form 10-K. There have been no material changes to our market risk during the three months ended March 31, 2026.
Item 4. CONTROLS AND PROCEDURES
Management carried out an evaluation, under the supervision and with the participation of its chief executive officer and chief financial officer, of the effectiveness of the design and operation of its disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of March 31, 2026, such disclosure controls and procedures are effective.
There were no changes in the Company's internal control over financial reporting during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
PART II—OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
Information pertaining to legal proceedings can be found in "Item 1. Financial Statements—Note 18. Legal Proceedings and Contingencies," to the interim consolidated financial statements, and is incorporated by reference herein.
Item 1A. RISK FACTORS
There have been no material changes from the risk factors disclosed in the Company's 2025 Form 10-K.
40
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table summarizes the surrenders of our equity securities during the three months ended March 31, 2026:
| Period | Total Number of Shares Purchased(a) | Average Price Paid per Share(a) | Total Number of Shares Purchased as Part of Publicly Announced Programs(b) | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs(b) | |||||||||||||||||||
| Dollars in millions, except per share data | |||||||||||||||||||||||
| January 1 to 31, 2026 | 48,345 | $ | 54.48 | — | $ | 5,014 | |||||||||||||||||
| February 1 to 28, 2026 | 13,108 | $ | 56.57 | — | $ | 5,014 | |||||||||||||||||
| March 1 to 31, 2026 | 2,442,613 | $ | 60.15 | — | $ | 5,014 | |||||||||||||||||
| Three months ended March 31, 2026 | 2,504,066 | — | |||||||||||||||||||||
(a)Includes shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive program.
(b)In May 2010, the Board of Directors authorized the repurchase of up to $3.0 billion of our common stock. From time to time thereafter, the Board approved additional share repurchase authorizations totaling an amount of $25.0 billion, including the most recent authorization of $3.0 billion in December 2023. The remaining share repurchase capacity under the program was $5.0 billion as of March 31, 2026. Our share repurchase program does not obligate us to repurchase any specific number of shares, does not have a specific expiration date and may be suspended or discontinued at any time.
Item 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangement
During the three months ended March 31, 2026, no director or officer of the Company adopted terminated
41
Item 6. EXHIBITS
Exhibits (listed by number corresponding to the Exhibit Table of Item 601 in Regulation S-K). The Exhibits designated by the symbol ‡‡ are management contracts or compensatory plans or arrangements.
| Exhibit No. | Description | |||||||
‡‡10a. | Form of 2026 Performance Share Units Award Agreement under the 2021 Stock Award and Incentive Plan (filed herewith). | |||||||
‡‡10b. | Form of 2026 Market Share Units Award Agreement under the 2021 Stock Award and Incentive Plan (filed herewith). | |||||||
‡‡10c. | Form of 2026 Restricted Stock Units Award Agreement with three-year, four-year, or five-year prorated vesting under the 2021 Stock Award and Incentive Plan (filed herewith). | |||||||
‡‡10d. | Form of 2026 Restricted Stock Units Award Agreement with three-year cliff vesting under the 2021 Stock Award and Incentive Plan (filed herewith). | |||||||
‡‡10e. | Form of 2026 Restricted Stock Units Award Agreement with two-year cliff vesting with a one-year post-vest holding period under the 2021 Stock Award and Incentive Plan (filed herewith). | |||||||
‡‡10f. | Form of 2026 Restricted Stock Units Award Agreement with one-year cliff vesting with a two-year post-vest holding period under the 2021 Stock Award and Incentive Plan (filed herewith). | |||||||
| 31a. | Section 302 Certification Letter (filed herewith). | |||||||
| 31b. | Section 302 Certification Letter (filed herewith). | |||||||
| 32a. | Section 906 Certification Letter (furnished herewith). | |||||||
| 32b. | Section 906 Certification Letter (furnished herewith). | |||||||
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | |||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | |||||||
* Indicates, in this Quarterly Report on Form 10-Q, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries. Gleevec is a trademark of Novartis AG; Keytruda and Winrevair are trademarks of Merck & Co., Inc., Rahway, NJ, USA; Plavix is a trademark of Sanofi; and Tecentriq is a trademark of Genentech, Inc. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.
42
SUMMARY OF ABBREVIATED TERMS
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
2025 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2025 | MZL | marginal zone lymphoma | ||||||||
| ANDA | Abbreviated New Drug Application | Mirati | Mirati Therapeutics, Inc. | ||||||||
| AstraZeneca | AstraZeneca PLC | NDA | New Drug Application | ||||||||
API | Active Pharmaceutical Ingredient | NTD | non-transfusion-dependent | ||||||||
AOCL | Accumulated other comprehensive loss | NHL | Non-Hodgkin's Lymphoma | ||||||||
| BioArctic | BioArctic AB | oHCM | Obstructive Hypertrophic Cardiomyopathy | ||||||||
| Celgene | Celgene Corporation | Ono | Ono Pharmaceutical Co., Ltd | ||||||||
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | PD-1 | programmed cell death protein 1 | ||||||||
cHL | classical Hodgkins Lymphoma | PD-L1 | programmed death-ligand 1 | ||||||||
| CVR | Contingent value right | PDUFA | Prescription Drug User Fee Act | ||||||||
Dr. Reddy's Laboratories | Dr. Reddy’s Laboratories, Limited and Dr. Reddy’s Laboratories, Inc. | Pfizer | Pfizer, Inc. | ||||||||
| EC | European Commission | PFS | progression-free survival | ||||||||
| EPS | earnings per share | PsA | psoriatic arthritis | ||||||||
| EU | European Union | Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 | ||||||||
Evotec | Evotec SE | R&D | research and development | ||||||||
| Exchange Act | the Securities Exchange Act of 1934 | RDFV | readily determinable fair values | ||||||||
| FASB | Financial Accounting Standards Board | REMS | risk evaluation and mitigation strategy | ||||||||
| FDA | U.S. Food and Drug Administration | Roche | F. Hoffman-La Roche & Co. | ||||||||
| GAAP | generally accepted accounting principles | RRMM | relapsed or refractory multiple myeloma | ||||||||
| GTN | gross-to-net | Sanofi | Sanofi S.A. | ||||||||
| HCM | hypertrophic cardiomyopathy | SEC | U.S. Securities and Exchange Commission | ||||||||
| HHS | Health and Human Services | SPC | Supplementary Protection Certificate | ||||||||
| IPRD | in-process research and development | SystImmune | SystImmune, Inc. | ||||||||
| IRA | Inflation Reduction Act of 2022 | TD | transfusion-dependent | ||||||||
| IRS | Internal Revenue Service | TNBC | triple negative breast cancer | ||||||||
IT | Information Technology | U.K. | United Kingdom | ||||||||
Merck | Merck & Co., Inc., Rahway, NJ, USA | U.S. | United States | ||||||||
MCL | mantle cell lymphoma | VAT | value added tax | ||||||||
MRD | minimal residual disease | ||||||||||
43
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BRISTOL-MYERS SQUIBB COMPANY (REGISTRANT) | |||||||||||
| Date: | April 30, 2026 | By: | /s/ Christopher Boerner, Ph.D. | ||||||||
Christopher Boerner, Ph. D. Chair of the Board and Chief Executive Officer | |||||||||||
| Date: | April 30, 2026 | By: | /s/ David V. Elkins | ||||||||
David V. Elkins Chief Financial Officer | |||||||||||
44
FAQ
How did Bristol-Myers Squibb (BMY) perform in Q1 2026?
Bristol-Myers Squibb generated $11,489 million in Q1 2026 revenue, a 3% increase year over year. GAAP diluted EPS rose to $1.31, while non-GAAP EPS declined to $1.58, reflecting the loss of diabetes royalty income.
What drove Bristol-Myers Squibb's revenue growth in Q1 2026?
Revenue growth came mainly from the Growth Portfolio, which increased 12% to $6,227 million, and from Eliquis, up 16% to $4,137 million. These gains offset sharp generic-driven declines in Revlimid, Pomalyst, Sprycel, and Abraxane.
Why did Bristol-Myers Squibb’s non-GAAP EPS fall in Q1 2026?
Non-GAAP EPS declined from $1.80 to $1.58 mainly because diabetes royalty income from AstraZeneca ended on December 31, 2025. This removed a high-margin revenue stream, outweighing benefits from lower amortization and ongoing cost savings initiatives.
How is government pricing policy affecting Bristol-Myers Squibb?
The Inflation Reduction Act and a 2025 U.S. Government Agreement are pressuring pricing, including a maximum fair price for Eliquis and providing Eliquis free to Medicaid. These measures may materially influence future revenues, margins, and cash flows across key products.
What are key pipeline and approval highlights for Bristol-Myers Squibb in early 2026?
The company reported positive Phase II/III results for several assets, including mezigdomide, Camzyos, Reblozyl and iza-bren, and FDA acceptance of an NDA for iberdomide. It also gained new approvals for Sotyktu in active PsA and Opdivo in classical Hodgkin lymphoma.
What restructuring and cost savings plans does Bristol-Myers Squibb have?
Bristol-Myers Squibb’s 2023 Restructuring Plan targets about $2.5 billion in charges through 2027, with $1.8 billion incurred to date. Combined with an expanded productivity initiative, the company expects roughly $2.0 billion in annual cost savings by the end of 2027.